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Transforming growth factor-β (TGF-β) is a cytokine that plays essential roles in
regulating embryonic development and tissue homeostasis. In normal cells, TGF-β
exerts an anti-proliferative effect. TGF-β inhibits cell growth by controlling a cytostatic
program that includes activation of the cyclin-dependent kinase inhibitors p15Ink4B and
p21WAF1/Cip1 and repression of c-myc. In contrast to normal cells, many tumors are
resistant to the anti-proliferative effect of TGF-β. In several types of tumors, particularly
those of gastrointestinal origin, resistance to the anti-proliferative effect of TGF-β has
been attributed to TGF-β receptor or Smad mutations. However, these mutations are
absent from many other types of tumors that are resistant to TGF-β-mediated growth
inhibition. The transcription factor encoded by the homeobox patterning gene DLX4 is
overexpressed in a wide range of malignancies. In this study, I demonstrated that DLX4
blocks the anti-proliferative effect of TGF-β by disabling key transcriptional control
mechanisms of the TGF-β cytostatic program. Specifically, DLX4 blocked the ability of
TGF-β to induce expression of p15Ink4B and p21WAF1/Cip1 by directly binding to Smad4
and to Sp1. Binding of DLX4 to Smad4 prevented Smad4 from forming transcriptional
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complexes with Smad2 and Smad3, whereas binding of DLX4 to Sp1 inhibited DNAbinding activity of Sp1. In addition, DLX4 induced expression of c-myc, a repressor of
p15Ink4B and p21WAF1/Cip1 transcription, independently of TGF-β signaling. The ability of
DLX4 to counteract key transcriptional control mechanisms of the TGF-β cytostatic
program could explain in part the resistance of tumors to the anti-proliferative effect of
TGF-β. This study provides a molecular explanation as to why tumors are resistant to
the anti-proliferative effect of TGF-β in the absence of mutations in the TGF-β signaling
pathway. Furthermore, this study also provides insights into how aberrant activation of a
developmental patterning gene promotes tumor pathogenesis.
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CHAPTER 1: INTRODUCTION

A. TGF-β SIGNALING AND CANCER

Transforming growth factor-β (TGF-β) is a cytokine that controls diverse
processes such as cell proliferation, differentiation and migration during normal
embryonic development and in adult tissues (1, 2). TGF-β signaling has a complex
role in tumors. On one hand, the anti-proliferative effect of TGF-β, which is essential
for maintaining normal tissue homeostasis, is lost in many cancers. On the other hand,
the ability of TGF-β to promote cell migration has an important role in tumor metastasis
(3, 4).

1. The TGF super-family

The TGF super-family is comprised of more than 30 secreted proteins, including TGFβs, activins and bone morphogenetic proteins (BMPs). These secreted proteins serve
as ligands for specific transmembrane type I and type II receptors (3) (Table 1).
Binding of the ligands to their specific type II receptor activates the corresponding type
I receptor, which in turn activates specific receptor-activated Smad proteins (R-Smads)
(Table 1). TGF-β and activin preferably activate Smad2 and Smad3, whereas Smad1,
Smad5 and Smad8 are selectively activated by BMPs (5). Activation of R-Smads is
inhibited by specific inhibitory Smad proteins (I-Smads) (i.e. Smad6, Smad7) (6, 7). All
R-Smads, irrespective of their ligands, associate with a common Smad protein,

1

Table 1. The TGF super-family: Ligands, receptors and signal transducers
Major TGF ligands, their corresponding receptors and receptor-regulated Smads (RSmads) are listed. All R-Smads interact with Smad4 as a common mediator (5, 9, 10).

Ligand

Type II receptor

Type I receptor

TGF-βs

TβRII

ALK5 (TβRI)

Activins

ActR-II

ALK4 (ActR-IB)

ActR-IIB

ALK7

BMPR-II

ALK3 (BMPR-IA)

ActR-II

ALK6 (BMPR-IB)

Nodals
Lefty

BMPs

R-Smad

Smad2
Smad3

Smad1
ActR-IIB

Smad5
ALK2

MIS

MISRII

?

?

ALK1

2

Smad8

Smad4, to form heteromeric complexes in the nucleus that control transcription of
distinct sets of genes (8).

1.1. TGF-β signaling pathways

Proteolytic cleavage of latent TGF-β releases a homodimeric complex of two
polypeptides linked by disulphide bonds (bioactive TGF-β) from latent TGF-β binding
proteins that tether the ligand in extracellular matrix (11). Binding of active TGF-β to
the TGF-β type II receptor (TβRII) activates its serine/threonine kinase domain and
recruits the TGF-β type I receptor (TβRI or ALK5). The TβRII kinase phosphorylates
TβRI at several serine and threonine residues located within its juxtamembrane
domain and thereby induces TβRI kinase activity (12). In turn, TβRI kinase
phosphorylates Smad2 and Smad3 that are tethered to the receptor complex by the
recruiting protein SARA. Phosphorylated Smad2 and Smad3 translocate into the
nucleus, where they form heteromeric complexes with Smad4 and other DNA-binding
factors to activate or repress transcription of distinct sets of genes (9, 12) (Figure 1).
As discussed in more detail below, this canonical Smad-dependent pathway is crucial
for mediating the anti-proliferative effect of TGF-β. Induction of cell migration by TGFβ is also controlled in part by the canonical Smad pathway (Figure 1). TGF-β can also
trigger signaling pathways that are Smad-independent. Interaction of TβRII and/or
TβRI with specific adaptor proteins activates distinct signaling pathways such as
mitogen-activated protein kinases (MAPK), phosphatidylinositol 3-kinase/Akt (PI3K/Akt) and Rho GTPases (13-16). These non-Smad signaling pathways are important
for promoting cell migration in response to TGF-β (17) (Figure 1).
3

Figure 1. The TGF-β signaling pathways
TGF-β induces activation of Smad and non-Smad signaling pathways. TGF-βmediated growth-inhibition is primarily controlled by the canonical Smad pathway.
TGF-β-mediated cell motility is controlled by both Smad and non-Smad pathways. RII:
TβRII, RI: TβRI.
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1.2. Modulation of TGF-β/Smad signaling

The Smad-dependent TGF-β signaling pathway is dynamically modulated at
multiple levels, from ligand-binding to downstream nuclear events (Figure 2). Binding
of TGF-β to TβRII is promoted by extracellular matrix proteins such as betaglycan,
endoglyn and crypto, and is blocked by LAP protein (reviewed in (11)). Stability of the
TβRI-TβRII complex is down-regulated by Smad7 that acts as an adaptor for the E3
ubiquitin ligases Smurf1 and Smurf2 (18, 19). Smad7 also prevents recruitment of RSmads to TβRI (20). Signaling pathways triggered by various growth factors such as
interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and epidermal growth factor
(EGF) can indirectly inhibit TGF-β signaling by inducing expression of Smad7
(reviewed in (21)). Nuclear localization and activation of R-Smads are induced by TβRI
phosphorylation, and are inhibited by phosphatases (22-24). Cytoplasmic retention of
R-Smads is also caused by extracellular signal-regulated kinase (ERK)-mediated
phosphorylation (25). TGF-β-induced Smad-dependent transcription is negatively
modulated by several Smad co-repressors. For example, binding of transforming
growth interacting factor (TGIF) to Smad2 represses transcription by recruiting histone
deacetylases (HDACs) to the Smad transcriptional complex (26). Another example is
the binding of Ski/SnoN to Smad transcriptional complexes that leads to recruitment of
N-CoR/mSin3/HDAC repressor complexes (27-29).

5

Figure 2. Modulation of TGF-β/Smad signaling
TGF-β/Smad signaling is modulated at multiple levels from ligand-binding to
downstream nuclear events. Several key "control-points" are indicated. Red lines
represent inhibition; blue arrows represent induction.
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2. Smad-mediated transcription

2.1. Functional domains of Smad proteins

Smad proteins are comprised of two functional domains, Mad homology 1
(MH1) and Mad homology 2 (MH2), with an intervening linker region (8, 12) (Figure 3).
MH1 domains contain nuclear localization signal (NLS) sequences and are
responsible for interacting with Smad-binding DNA elements (SBE). MH2 domains are
highly conserved between R-Smads. MH2 domains mediate interactions of R-Smads
with TβRI, with one another, with Smad4, and with other transcription factors (12).
Phosphorylation of two serine residues at the unique C-terminal Ser-Ser-X-Ser (SSXS)
motif by TβRI kinase results in nuclear localization and activation of R-Smads (30, 31).
Conversely, phosphorylation of linker domains by ERKs causes cytoplasmic retention
of R-Smads. Linker domains are divergent among R-Smads and Smad4. The linker
region of Smad4 possesses a nuclear export signal (NES) (Figure 3). This NES and
the NLS signal, located in the MH1 domain, allow Smad4 to shuttle in and out of the
nucleus (Figure 3).

7

Figure 3. Functional domains of Smad proteins
MH1 domains of Smad4 and R-Smads contain a nuclear localization signal (NLS).
Smad4 also contains a nuclear export signal (NES). The MH1 domains mediate DNA
binding. Smad2 contains an extra 30 amino acids (yellow box) that abrogates its DNAbinding ability. MH2 domains of R-Smads contain the SSXS motif that is
phosphorylated by TβRII kinase. Adapted with permission from Wiley‐Liss, Inc: JCB,
Kimberly et al., copyright 2007 (32)
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2.2. Smad-mediated transcription regulation

TGF-β induces formation of R-Smad/Smad4 complexes either as hetero-trimers
(two R-Smads + Smad4) or as hetero-dimers (one R-Smad + Smad4) (33). The
binding affinity of Smad MH1 domains to SBEs (5’-AGAC-3’) is very low (33).
However, high DNA-binding affinity and specificity are achieved by interaction of Smad
hetero-dimers or -trimers with other DNA-binding factor(s) to form large transcriptional
complexes that either induce or repress specific sets of target genes (8, 34, 35).

Smad-mediated transcription induction

Both the strength and specificity of Smad-induced transcription are governed by
interactions between activated R-Smads, Smad4, and specific transcriptional
activators with their corresponding DNA-binding elements on target promoters. A
classic example is the induction by TGF-β of expression of the cyclin-dependent
kinase (CDK) inhibitor p15Ink4B. The proximal promoter region of the p15Ink4B gene
(positions −110/−40) contains two adjacent sets of SBEs and GC boxes that are
bound by the transcription factor Sp1 (36). TGF-β induces p15Ink4B transcription by
stimulating cooperative interactions between Sp1 and Smad proteins that enhance
their DNA-binding and transcriptional activities (Figure 4A). Transcriptional activation
by TGF-β of the gene encoding the CDK inhibitor p21WAF1/Cip1 is also mediated by
cooperative interactions between Sp1 and Smads. This is achieved via two distinct
promoter regions, a distal region (located 1.7 kb upstream of the transcription start
site) that contain SBEs, and a proximal region (located between positions −124 to −61)

9

Figure 4. Smad-mediated transcriptional activation
Smads can induce transcription of target genes by [A] recruiting transcriptional
activators (e.g. Sp1) and/or histone acetylases (e.g. CBP/p300) and by [B] displacing
transcriptional repressors (e.g. Brk).
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that have Sp1-binding sites (37, 38). It is thought that coupling of the distal and
proximal promoter elements and formation of the Smad-Sp1 transcription complex
occurs via chromatin remodeling (10, 34, 39). Increasing evidence indicates that the
histone acetyltransferase CBP/p300 is a major co-activator for Smad-mediated
transcriptional activation (40-43) (Figure 4A). Smads also can activate specific genes
by displacing transcriptional repressors. For example, binding of MAD (Drosophila
homolog of R-Smad) to the Dpp (Decapentaplegic) promoter dislodges the Brk
(Brinker) repressor from the Dpp promoter (44) (Figure 4B).

Smad-mediated transcription repression

Although Smad proteins have intrinsic trans-activating activity, gene repression
accounts for about one-quarter of TGF-β-mediated gene responses (45). Mounting
evidence implicates a central role for Smad3, but not Smad2, in TGF-β-mediated
transcription repression. A well-studied example is TGF-β-mediated repression of cmyc transcription (Figure 5A). Smad3 binds to the co-repressor p107 in a complex
with E2F4/5 and DP1. In response to TGF-β stimulation, this complex translocates into
the nucleus and interacts with Smad4 via Smad3. Smad4 binds to the SBE, while
E2F4/5 binds to the E2F binding site. The E2F binding site and the SBE are both
located within the TGF-β inhibitory element (TIE) of the c-myc promoter. Interaction of
E2F4/5-DP1-p107-Smad3-Smad4 repressive complex with the TIE element blocks cmyc transcription (46, 47) (Figure 5A). On the other hand, Id1 transcription is blocked
by the Smad co-repressor ATF3. ATF3 forms inhibitory complexes with Smad3 and
Smad4, and ATF3 expression itself is induced by Smads (48). Smad3 also represses
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Figure 5. Smad-mediated transcriptional repression
Smads can repress transcription of target genes by [A] recruiting transcriptional
repressors (e.g. p107), [B] recruiting HDACs (e.g. HDAC4), and [C] sequestering
transcriptional activators (e.g. MyoD).

12

transcription by recruiting HDACs. Smad3 blocks osteoclacin expression by binding
Runx2 and recruiting HDAC4 to form a repressive complex that inhibits Runx2-induced
osteoclacin transcription (49) (Figure 5B). In addition to recruiting repressors, Smad3
blocks binding of transcriptional activators to target gene promoters. For example,
Smad3 inhibits transcription of the muscle creatine kinase (MCK) gene by binding
MyoD and blocking formation of MyoD-E12/47 dimers and their binding to the E-box
motif (50) (Figure 5C).

3. Cellular responses to TGF-β

3.1. TGF-β-mediated growth inhibition

In most types of normal cells, TGF-β has a potent anti-proliferative effect. TGFβ primarily inhibits cell growth by inducing cell cycle arrest in G1 phase (3). TGF-β
controls a cytostatic program of gene responses that includes activation of CDK
inhibitors and repression of growth-promoting transcription factors (Figure 6). Gene
responses that are central to this program are induction of p15Ink4B and p21WAF1/Cip1
(38, 51) and repression of c-myc and inhibitors of differentiation (Ids) (3, 48, 52). Each
of these gene responses leads to G1 arrest by distinct but integrated mechanisms.
p15Ink4B forms an inactive complex with CDK4/6 that prevents activation of CDK4/6 by
cyclin D (53) (Figure 6). Conversely, p21WAF1/Cip1 binds to and inhibits cyclin A/D/ECDK2 and cyclin D-CDK4/6 complexes

(54) (Figure 6). E2F family members are

crucial for G1/S transition and S phase progression (55). Inhibition of CDKs keeps the
Rb protein in an unphosphorylated and active form such that Rb is able to bind and
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Figure 6. TGF-β induces cell cycle arrest
TGF-β induces expression of the CDK inhibitors, p15Ink4B and p21WAF1/Cip1, and inhibits
expression of c-myc and Id transcription factors. Induction of p15Ink4B and p21WAF1/Cip1
and down-regulation of c-myc and Ids lead to increased repression by Rb protein of
the E2F transcription factors that normally promote G1 to S phase progression. Red
lines represent inhibition; blue arrows represent induction.
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block transcriptional activity of E2F proteins (56) (Figure 6). On the other hand, c-myc
induces expression of cdc25A which dephosphorylates and activates Cdk4/6 (57)
(Figure 6). TGF-β also inhibits expression of Id1, Id2 and Id3 (3, 48, 58). Binding of Id
proteins to unphosphorylated Rb dislodges Rb from E2F transcription factors, thereby
releasing E2Fs from the inhibitory effect of Rb (59) (Figure 6). As discussed above
(section 2), transcriptional activation of p15Ink4B and p21WAF1/Cip1, and repression of cmyc and Ids occur in a Smad-dependent manner (Figures 4, 5). However, there is
evidence that TGF-β can also induce G1 arrest by a Smad-independent mechanism. It
has been reported that TGF-β induces protein phosphatase 2A (PP2A) that
dephosphorylates and deactivates p70S6K, a kinase that plays a role in G1/S
progression (60, 61). The TGF-β cytostatic program is tightly integrated by feedback
loops that protect against competing mitogenic signals. c-myc represses transcription
of p15Ink4B and p21WAF1/Cip1, but its own transcription is repressed by TGF-β (46, 62,
63) (Figure 7). TGF-β/Smad signaling inhibits Id2 expression by repressing expression
of c-myc, an activator of Id2 transcription, and by inducing expression of the c-myc
antagonist MAD4 (58, 64).

The role of TGF-β in programmed cell death varies depending on the cell type
and cellular conditions (65-69). Several genes that are induced in a Smad-dependent
manner can promote apoptosis. For example, TIEG, an early response gene induced
by TGF-β, induces apoptosis in pancreatic epithelial cell lines (68). On the other hand,
activation of several Smad-independent pathways by TGF-β can inhibit apoptosis.
TGF-β blocks serum withdrawal-induced apoptosis by suppressing JNK activity in lung
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Figure 7. Integrated control of the TGF-β cytostatic program
The TGF-β cytostatic program is tightly integrated by feedback loops that protect
against competing mitogenic signals. For example, c-myc represses transcription of
p15Ink4B and p21WAF1/Cip1. On the other hand, c-myc transcription is repressed by TGFβ.
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carcinoma cells and Akt activity in mammary epithelial cells and skin keratinocytes (65,
67). However, the program of TGF-β-mediated apoptosis is not well-defined (3)

3.2. TGF-β-induced cell motility

During normal developmental patterning and tissue repair, cells often acquire
migratory and invasive properties (2). In response to TGF-β, epithelial cells acquire
fibroblastic morphology and become motile and invasive. The hallmarks of this
conversion, termed epithelial-to-mesenchymal transition (EMT), are cytoskeletal
reorganization (actin reorganization, stress fiber formation), junctional disassembly
(dissolution of tight junctions, adherens junctions and desmosomes) and loss of apicalbasolateral polarity (2, 17).

TGF-β promotes EMT in part by inducing expression of transcription regulators
that belong to the Snail, ZEB and bHLH families in a Smad-dependent manner (Figure
8). These transcription factors repress expression of major transmembrane
components of adherens and tight junctions of epithelial cells, and conversely activate
expression of mesenchymal genes (2). Snail1 and Snail2 (Slug) repress expression of
E-cadherin, plakoglobin, claudins and occludin (70-72). Conversely, Snail proteins
induce expression of vimentin, fibronectin, vitronectin and N-cadherin (73, 74),
extracellular matrix proteins (collagen type III and V) (73) and regulators of migration
and invasion (RhoB, plasminogen activator inhibitor-1, matrix metalloproteinase MMP9) (74, 75). ZEB1 and ZEB2 (SIP1) repress expression of E-cadherin (76, 77),
desmosome protein plakophilin-2 and tight junction proteins claudin-4 and ZO-3, and
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Figure 8. Induction of EMT and cell motility by TGF-β
TGF-β promotes EMT and cell motility by both Smad-dependent and Smadindependent (non-Smad) mechanisms. EMT-inducing transcription factors (Snail, ZEB
and bHLH families) are induced by TGF-β in a Smad-dependent manner. These
transcription factors repress expression of epithelial genes and activate expression of
mesenchymal genes. Activation of non-Smad signaling pathways by TGF-β enhances
cell motility by inducing cytoskeletal reorganization and junctional disassembly.
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conversely enhance expression of vimentin, N-cadherin and MMP-2 (78). The bHLH
transcription factor members Twist1 and Twist2 repress expression of E-cadherin,
occludin and claudin-7, and induce vimentin and N-cadherin (79).

Increasing studies indicate the importance of non-Smad signaling pathways in
TGF-β-induced EMT (Figure 1). Inhibition of the MAPK, Rho GTPase and PI3-K/Akt
pathways blocks TGF-β-induced EMT in epithelial cells (13, 80-83). Activation of
MAPK members is mediated via different TGF-β receptor adaptor proteins. TRAF6
activates TAK1 which in turn activates p38 MAPK and c-Jun N-terminal Kinase (JNK)
(84, 85). Shc activates Ras which then activates ERK1 and ERK2 (86). ERK1/2
indirectly regulate genes that control cell-matrix interactions, cell motility and
endocytosis (45). Activation of MAPK signaling induces junction disassembly and cell
motility (reviewed in Ref. (87, 88)). TGF-β induces rapid activation of Rho GTPases.
Activated RhoA induces p160ROCK (RhoA kinase) (89) which induces stress fiber
formation and stimulates LIM kinase. Induction of cofilin by LIM kinase causes reorganization of the actin cytoskeleton (90, 91). Conversely, RhoA activity is controlled
by Par6 that activates the E3 ubiquitin ligase Smurf1, which in turn controls RhoA
activity at tight junctions by targeting it for degradation (14). TGF-β induces interaction
of the regulatory subunit of PI3-K with TβRI receptor resulting in rapid activation of the
PI3-K/Akt signaling pathway (16). Activation of this signaling leads to reduced cell-cell
adhesion and the acquisition of spindle cell morphology (13, 92, 93). Akt has been
reported to repress transcription of E-cadherin (93), induce expression of
metalloproteinases (94) and induce delocalization of E-cadherin, ZO-1 and integrin-β1
from cell junctions (13).
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4. Complex role of TGF-β in tumorigenesis

Tumorigenesis is a dynamic process characterized by multiple acquired
capabilities that include insensitivity to anti-growth signals, limitless replicative
potential, self-sufficiency in growth signals, evasion of apoptosis, sustained
angiogenesis and tissue invasion (95). TGF-β plays a complex role in tumorigenesis
by facilitating the cancer cell's acquisition of these key capabilities (21, 95) (Figure 9).

4.1. Promotion of tumor progression by TGF-β

TGF-β promotes tumor progression by exerting both cell-autonomous and noncell-autonomous effects. The cell-autonomous effect of TGF-β is the recapitulation of
normal TGF-β-induced EMT and is crucial for tumor metastasis (2, 9). Blockade of
TGF-β signaling inhibits tumor cell invasiveness, whereas restoring TGF-β signaling in
non-invasive tumor cells promotes invasiveness (96). TGF-β also promotes tumor
progression by exerting non-cell-autonomous effects on the tumor microenvironment.
TGF-β promotes tumor angiogenesis in part by inducing expression of angiogenic
cytokines, and also MMP-2 and MMP-9 that induce endothelial cell migration and
invasion (97-100). Furthermore, TGF-β causes immunosuppression and enables
tumor cells to escape from immunosurveillance (101-103). TGF-β represses the
function of cytotoxic T cells by inhibiting expression of interleukin-2 and its receptors,
which are crucial for T-cell proliferation (104, 105). TGF-β causes loss of tumor cell
immunogenicity by repressing expression of major histocompatibility complex antigens
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Figure 9: Multiple roles of TGF-β in tumorigenesis
TGF-β signaling has a complex role in tumorigenesis. TGF-β induces migratory
behavior of normal cells and promotes metastasis of tumor cells. TGF-β also promotes
tumor angiogenesis and immunosuppression. TGF-β inhibits proliferation, induces
apoptosis and maintains genomic stability in normal cells. The anti-proliferative effect
of TGF-β is lost in many cancers.
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(106-108). TGF-β also inhibits activity of other immune cells such as killer cells, NK
cells (109), neutrophils (110), macrophages and B cells (102, 111).

4.2. Resistance of tumors to the anti-proliferative effect of TGF-β

A major hallmark of cancer is acquired insensitivity to anti-growth signals (95).
In many normal cell types, TGF-β has a potent anti-proliferative effect. However, many
tumors are resistant to the anti-proliferative effect of TGF-β (3, 4, 39). Mutations of
some core components of the TGF-β signaling pathway such as TβRI, Smad2 and
Smad3 are rarely found (<5%) in cancers (39, 112). However, resistance to the
growth-inhibitory effect of TGF-β in some cancers has been attributed to mutations in
other core components, in particular, TβRII and Smad4 (Table 2). Inactivation of TβRII
due to somatic mutations has been reported to occur at high frequency (60-90%) in
colon cancers with microsatellite instability (MSI) (112-114). Mutations or deletions of
Smad4 have been reported in ~50% of pancreatic and non-MSI colorectal cancers
(112, 115). TGF-β receptor mutations have been found in 12-31% of ovarian cancers
(116, 117) but many ovarian cancers that are resistant to TGF-β were reported to
express functional receptors (118). However, mutations in TβRII and Smad4 are rarely
found in various other types of cancers such as lung and prostate cancers (112, 119121) (Table 2). Similarly, many TGF-β-resistant breast cancers rarely contain TGFβRII or Smad mutations (122, 123) (Table 2). The rareness of mutations in core
components of the TGF-β signaling pathway in many tumors therefore indicates that
resistance to TGF-β also stems from other aberrations.
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Table 2. Mutation frequency of TGF-β signaling components in cancers
Mutation frequency of TβRII and Smad4 genes in some types of cancers are listed.
+MSI: Cancer with microsatellite instability, -MSI: Cancer with no microsatellite
instability. nd: Not detected. Mutations which are rarely detected are indicated as <5%:

Cancer

TβRII Gene

Smad4 Gene

Colon

60-90% (+MSI)

50% (-MSI)

Pancreas

4%

50%

(125)

Ovary

12-31%

12%

(116, 117)

Lung

nd (+MSI)

7%

(119, 121)

Prostate

<5%

<5%

(120)

Breast

<5%

<5%

(122, 123)
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Reference
(113-115, 124,
125)

B. ABERRATIONS OF HOMEOBOX GENES IN HUMAN CANCERS

Homeobox genes comprise a large super-family of evolutionarily conserved
genes that encode transcription factors (126, 127). Homeobox genes play essential
roles in controlling developmental patterning (127-130). Many homeobox genes are
aberrantly expressed in tumors, but the functional significance of their aberrant
expression is poorly understood (131).

1. Overview of homeobox genes

Transcription factors encoded by homeobox genes are characterized by their
highly conserved 61 amino acid DNA-binding domain termed the homeodomain. This
domain forms three alpha helices that bind DNA elements containing a TAAT core
motif (127) (Figure 10). The homeobox gene super-family is categorized into several
different families based on sequence similarities in their homeodomain and other
functional motifs (132, 133) (Figure 11). Members of the HOX and DLX homeobox
gene families are organized in clusters. In mammals, the 39 members of the HOX
family are organized in four clusters located on different chromosomes. The 6
members of the DLX family are located upstream of these HOX loci (134, 135) (Figure
12). These HOX-DLX clusters have been postulated to derive from gene duplication
during evolution (128, 136).
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Figure 10. Structure of homeodomain proteins
Transcription factors encoded by homeobox genes contain a conserved homeodomain
that binds DNA. The homeodomain forms three α-helixes (colored boxes) that bind
DNA sequences containing a TAAT core motif. Adapted with permission from Nat Rev
Cancer, Abate-Shen, copyright 2002 (131).
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Figure 11. Classification of homeobox genes
The homeobox gene super-family comprises more than 200 genes that are
categorized into different families. The DLX family comprises six members.
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Figure 12. Gene clusters of DLX and HOX families
Members of the mammalian HOX and DLX homeobox gene families are organized in
clusters. The 39 members of the HOX family are organized in four clusters located on
different chromosomes. The 6 members of the DLX family are located upstream of
these HOX loci. Adapted with permission from Springer: Cell, Krumlauf, copyright
1994 (128).
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2. Homeobox genes in development and cancer

Homeobox genes play essential roles in controlling cell differentiation, tissue
morphogenesis and specification of the body plan during embryonic development.
Distinct sets of homeobox genes control organogenesis, development of the central
nervous system, limb and skeletal patterning, and craniofacial morphogenesis (137,
138). Homeobox genes also control cell renewal and tissue regeneration processes in
adults, including hematopoiesis, spermatogenesis and endometrial remodeling during
the menstrual cycle (139-143). Aberrant expression of various homeobox genes has
been reported in different types of tumors (Tables 3, 4). A general trend is that
homeobox genes that are normally expressed in differentiated adult tissues are downregulated in tumors, whereas homeobox genes that are normally expressed in
embryonic tissues are activated in tumors (131, 144) (Figure 13). This aberrant
expression of homeobox genes in tumors is thought to reflect an inappropriate
recapitulation of embryonic pathways (131, 144). Several homeobox genes that are
down-regulated in tumors have tumor-suppressive functions (144) (Table 3). Loss of
function of these homeobox genes appears to drive cells back to a less differentiated
state and promotes cell survival and proliferation (144). Down-regulated expression of
several homeobox genes in tumors has been attributed to epigenetic mechanisms and
chromosomal aberrations. For example, loss of HOXA5 expression in breast tumors is
due to promoter methylation (145). Loss of NKX3.1 and CUTL1 expression in prostate
and uterine cancers stems from loss of heterozygosity (146, 147). On the other hand,
aberrant activation of several homeobox genes that are normally expressed in
embryonic tissues promotes tumor cell proliferation and survival (Table 4). Aberrant
expression of homeobox genes in leukemias primarily arises from chromosomal
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Table 3. Examples of homeobox genes that are down-regulated in tumors

Gene

Cancer ()

Normal expression pattern

Functional significance

Reference

CDX2

Colon ()

Expressed in adult intestinal

Inhibits growth of colon carcinoma

(149-152)

epithelium

cells by inducing expression of
p21WAF1/Cip1. Heterozygous deletion
increases susceptibility to
carcinogenesis.

NKX3.1

Prostate ()

Expressed in adult prostate

Null mutant mice are predisposed to

epithelium

prostate cancer. Loss of expression

(146, 153, 154)

correlates with tumor progression.
HOXA5

Breast ()

Expressed in normal breast

Regulate p53 expression .Loss of

epithelium.

expression was found in 60% of

(145, 155)

breast cancer to be due to promoter
methylation.
BARX2

Ovary ()

Expressed in normal adult

Has tumor suppressive and anti-

ovarian surface epithelium

metastatic properties. Can modulate
cisplatin sensitivity. Frequently
deleted in ovarian cancer
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(156, 157)

Table 4. Examples of homeobox genes that are up-regulated in tumors

Gene

Cancer ()

Normal expression pattern

Expression and Function in tumors

Reference

PAX2

Renal ()

Expressed during embryonic

Expressed in renal cell carcinomas.

(158-161)

urogenital development but

Promotes cancer cell survival.

not in adult kidney.
HSIX1

Breast ()

Expressed in developing

Promotes cell cycle progression by

eye, brain, muscle,

activating cyclin A1 expression.

(162, 163)

embryonic mammary gland.
GBX2

HOXB7

Prostate ()

Expressed in developing

Induces cell growth by inducing

nervous system.

expression of interleukin-6.

Melanoma

Promotes tumor growth and
angiogenesis by inducing expression of

Ovarian

fibroblast growth factor-2. Induces EMT.
Breast
Promotes DNA repair.
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(164, 165)

(166-169)

Figure 13. Aberrant expression of homeobox genes in tumors
Homeobox genes that are expressed during embryonic development, but are downregulated in normal adult tissues, are often up-regulated in tumors. Conversely,
homeobox genes that are expressed in normal adult tissues are often down-regulated
in tumors. Adapted with permission from Nat Rev Cancer, Abate-Shen, copyright 2002
(131).
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translocations. Several chimeric oncoproteins arise from fusion of the NUP98 gene
and HOX genes (144, 148). However, the mechanisms that give rise to activation of
homeobox genes in solid tumors are largely unknown.

3. Significance of the homeobox gene DLX4 in cancer

Most homeobox genes are expressed in a tissue-specific manner. DLX4, a member of
the DLX homeobox gene family, is expressed in normal bone marrow cells,
trophoblast, placenta and endometrium, but is not expressed in most other normal
adult tissues (170-172). DLX4 has been increasingly reported to be expressed in
diverse types of tumors (Table 5). The DLX4 gene maps to the 17q21.3-q22 region
(173, 174). Amplification of this chromosomal hot-spot in breast and ovarian cancers
correlates with poor prognosis (175). Aberrant expression of DLX4 in ovarian cancers
is significantly associated with high tumor grade and advanced disease stage (173).
Aberrant expression of DLX4 in breast cancers correlates with invasiveness (176).
Upregulation of DLX4 has also been reported in other types of cancers, including
leukemia, choriocarcinoma, prostate and lung cancers (172, 177-179). The
upregulation of DLX4 in tumors arising from a wide variety of organ sites raises the
strong possibility that DLX4 controls a pathogenic mechanism that is common to
multiple types of tumors.
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Table 5. Aberrant expression of DLX4 in tumors

Cancer
Ovarian

Expression pattern in tumors

Functional significance

Reference

Expressed in ovarian carcinomas

Induces tumor vascularization by inducing

(173)

and correlates with high tumor grade

expression of VEGF and FGF-2.

and disease stage.
Breast

Highly expressed in invasive tumors.

Represses expression of BRCA1. Induces

(176, 187-

expression of bcl-2 and inhibits TNF-α-

190)

induced apoptosis in breast cancer cells.
Leukemia

Highly expressed in chronic

Expression in leukemic cells increases

lymphocytic leukemia and acute

clonogenicity.

(172)

lymphoblastic leukemia.
Prostate

Expressed in 70% of prostatic

(177)

adenocarcinomas.
Lung

Expressed at higher levels in tumors

Enforced expression of DLX4 in metastatic

than in adjacent normal tissues.

lung cancer cells inhibits metastasis.

Chorio-

Expressed in placenta and

Promotes tumor cell survival

carcinoma

choriocarcinoma cell lines
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(178, 179)

(191, 192)

C. CROSS-REGULATION OF TGF SIGNALING AND HOMEOBOX GENES

Increasing evidence indicates that cross-talk between members of the TGF
super-family and of the DLX homeobox gene family is important for controlling normal
bone morphogenesis and skeletal patterning (1, 180, 181). On one hand, signaling by
several TGF super-family members controls transcriptional activity and/or expression
of DLX transcription factors. For instance, BMP-2 activates DLX3 transcription (182).
In contrast, Smad6, an antagonist of BMP signaling, inhibits transcriptional activity of
DLX3 by inhibiting its ability to bind target gene promoters (183). On the other hand,
DLX proteins can control TGF signaling by modulating Smad activities. DLX1 has
been reported to inhibit activin signaling by binding Smad4 (184). Cross-regulation
between members of the TGF super-family and other homeobox genes has also been
reported. For example, Mixer and Milk, members of the homeobox Mix family,
enhance Smad-mediated transcription of Goosecoid in xenopus by interacting and
recruiting activated Smad complexes to Mixer/Milk binding sites on the Goosecoid
promoter (181). Group 13 HOX proteins interact with Smad1, Smad2 and Smad5 and
block their transcriptional activities (185). Conversely, Smad1 has been reported to
block transcriptional activity of HOXB4, HOXB7, HOXC8 and HOXD10 (186).
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D. HYPOTHESIS AND SPECIFIC AIMS

The resistance to anti-growth signals is a major hallmark of cancer. TGF-β is a
key cytokine that inhibits growth of most normal cells by inducing G1 arrest (Figure 6).
The anti-proliferative effect of TGF-β is orchestrated by a cytostatic program of gene
responses that are controlled by Smad-dependent mechanisms (Figure 1). Central to
this cytostatic program are activation of the CDK inhibitors, p15Ink4B and p21WAF1/Cip1,
and repression of the growth-promoting transcription factors, c-myc and Ids (Figure 6).
Binding affinity and selectivity of Smad complexes for target gene promoters are
governed by Smad interactions with other DNA-binding factors. Cooperative
interactions between Smad proteins and the Sp1 transcription factor are central to
TGF-β-mediated induction of p15Ink4B and p21WAF1/Cip1 transcription (Figure 4A). Most
types of cancers are resistant to the anti-proliferative effect of TGF-β. This resistance
has been attributed to TGF-β receptor and/or Smad mutations in some types of cancer
(Table 2). However, the rareness of these mutations in many other tumors indicates
that resistance to the anti-proliferative effect of TGF-β also stems from other molecular
aberrations (Table 2).

DLX4 is a member of the DLX homeobox gene family. Unlike most other
homeobox genes that have been studied to date, DLX4 is expressed in a wide range
of different malignancies. Mounting evidence indicates that cross-talk between the
members of the TGF super-family and DLX genes is important for controlling normal
bone morphogenesis and skeletal patterning (Section C). My central hypothesis is that
DLX4 promotes tumor growth by modulating the TGF-β signaling pathway in tumors.
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My overall goal is to determine whether and how DLX4 blocks the anti-proliferative
effect of TGF-β in tumors.

The specific aims of my thesis project are to determine:
1) whether DLX4 inhibits TGF-β-induced, Smad-dependent responses
2) whether DLX4 blocks Smad transcription activity
3) whether DLX4 represses Smad/Sp1-mediated transcription
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CHAPTER 2: MATERIALS AND METHODS

1. Plasmids

A BP1 cDNA that contains the full-length coding region of human DLX4 (172)
was provided by Dr. Patricia Berg (George Washington University). FLAG-tagged
DLX4 was cloned into the pIRES-EGFP2 and pRetroQ vectors (Clontech, Palo Alto,
CA). DNA fragments encoding different DLX4 domains were subcloned into pET41
GST vectors (Novagen, Gibbstown, NJ) as described in Figure 29A. DLX4 shRNAs
and non-targeting shRNAs were purchased from OriGene Technology (Rockville, MD).
GST-tagged Smad2 and Smad4 plasmids were provided by Dr. Fang Liu (Rutgers
University). Smad2, Smad3 and Smad4 cDNAs were purchased from OriGene
Technology. MH2 and linker domains of Smad2 and Smad3, described in Figure 23,
were subcloned into the pFA-CMV plasmid containing the GAL4-DBD (Stratagene, La
Jolla, CA). The GAL4-driven pRF-Luc reporter construct was also purchased from
Stratagene. The pGL2 F-Luc reporter vector was purchased from Promega. The c-myc
promoter reporter construct, pBV-MYC(Del4) and pSBE4-Luc reporter construct
containing four tandem SBE elements (193, 194) were provided by Dr. Bert Vogelstein
(Johns Hopkins University). The Cignal Sp1 reporter construct containing a synthetic
promoter comprising tandem Sp1-binding sites was purchased from SABiosciences
(Frederick, MD). Sp1 cDNA was provided by Dr. Keping Xie (MD Anderson Cancer
Center). pGL3 reporter constructs (p15-WT and p15-SBE-mt) containing wild-type and
mutant p15Ink4B promoter sequences (51) were provided by Drs. Xiao-Fan Wang (Duke
University Medical Center) and Xin-Hua Feng (Baylor College of Medicine). The Id1
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promoter construct was provided by Dr. Robert Benezra (Memorial Sloan-Kettering
Cancer Center) (195). The BRE-Luc reporter construct (196) was provided by Dr.
Peter ten Dijke (Netherlands Cancer Institute).

2. Antibodies and other reagents

Antibodies (Abs) were purchased from commercial sources as follows: DLX4
Abs for immunoblotting Abcam (Cambridge, MA) and Abnova Corporation (Taipei,
Taiwan), for immunoprecipitation (Santa Cruz Biotechnology, Santa cruz, CA).
Smad2, phospho-Smad2 (Ser465/467), Smad3, Smad4, p15Ink4B, c-myc (Cell
Signaling Technology, Danvers, MA); p21WAF1/Cip1 (Calbiochem, Gibbstown, NJ); Sp1,
E-cadherin (Zymed Laboratories, Carlsbad, CA); N-cadherin (BD Biosciences, San
Jose, CA); actin, FLAG-M2 (Sigma-Aldrich, St. Louis, MO); lamin A/C and Smad2/3
(Santa Cruz Biotechnology), HRP-conjugated secondary Abs (Bio-Rad, Hercules, CA),
Alexa Fluor 594-conjugated secondary Abs (Invitrogen, Carlsbad, CA). Recombinant
Sp1 protein, TGF-β and BMP-4 were purchased from Promega (Madison, WI), SigmaAldrich and R&D Systems (Minneapolis, MN), respectively.

3. Cell lines

HepG2 cells were provided by Dr. Michelle Barton (MD Anderson Cancer
Center). Mv1Lu cells were purchased from American Type Culture Collection
(Manassas, VA). Both cell lines were cultured in MEM medium supplemented with
10% FBS, 2mM glutamine and penicillin-streptomycin. NMuMG and MDA-MB-468
cells were purchased from American Type Culture Collection (Manassas, VA) and
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cultured in GIBCO® RPMI-1640 Medium supplemented with 10% FBS, 2mM
glutamine and penicillin-streptomycin. Ampho-293 cells (provided by Dr. Douglas
Boyd, MD Anderson Cancer Center) and MCF-7 cells (provided by Dr. Francois-Xavier
Claret, MD Anderson Cancer Center) were cultured in DMEM medium supplemented
with 10% FBS, 2mM glutamine and penicillin-streptomycin.

4. Protein over-expression and knock-down

For generating stable lines, FLAG-tagged DLX4 cDNA was subcloned into the
pRetroQ vector (Clontech) and the retroviral construct was used to transfect Ampho293 cells. Supernatants were harvested 2 days thereafter and used to infect target
cells. Stable lines were selected by puromycin (0.5 µg/ml). For studying Smaddependent growth inhibition, Smad4 was transiently expressed in MDA-MB-468 cells
that lack Smad4. For transient expression, cells were transfected with recombinant
plasmids using FuGENE6 reagent following manufacturer's instructions (Roche
Applied Biosciences, Indianapolis, IN). To assay the effect of DLX4 knock-down, MCF7 cells were transfected with shRNA constructs (empty vector, non-targeting and two
DLX4 shRNAs) purchased from OriGene Technology using FuGENE6 reagent.

5. Cell growth assays

Cells were seeded in 96-well plates at 4,000 cells per well in 100 µl medium
and cultured for 2 days in complete medium containing 0, 1, 3, 10, 30 and 100 ng/ml
TGF-β. MTT assays were performed following manufacturer's instructions (Roche
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Applied Biosciences). Briefly, 10 µl of MTT labeling reagent was added to each well
(final MTT concentration 0.5 mg/ml). The plate was incubated for 4 hours in a
humidified atmosphere (37°C, 5% CO2) then 100 μl of solubilization solution was
added to each well. The plate was incubated overnight in a humidified atmosphere.
The spectrophotometrical absorbance (570 nm) was measured. Experiments were
done in triplicate and repeated two times.

6. Cell cycle analysis

Cells were seeded in 10 cm dishes to reach 30% confluence the following day.
Cells were serum-starved overnight and then cultured in complete medium with and
without addition of TGF-β (10 ng/ml) for 18 h. Cells were harvested and washed in
phosphate-buffered

saline

(PBS).

Cells

were

then

fixed

in

1

ml

of

4%

paraformaldehyde in PBS (pH 7.4) for 20 minutes on ice. Cells were washed in PBS,
resuspended in 1 ml of cold 70% ethanol and kept at -200C. Following centrifugation at
800 x g, cells were washed with PBS then stained with 1 ml of staining solution
containing 40 μg/ml propidium iodide (Sigma-Aldrich) and RNaseA at 370C for 30
minutes in the dark. Distribution throughout the cell cycle was determined by flow
cytometric analysis.

7. Reporter Assays
Cells were seeded at 4–5 x 104 cells/well in 12-well plates and co-transfected
with expression plasmids (400 ng), reporter plasmid (100 ng) and pRL-CMV Renilla
luciferase (R-Luc) reporter plasmid (0.5 ng) (Promega) for normalizing transfection
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efficiency using FuGENE6 reagent (Roche Applied Biosciences). At 24 hours after
transfection, cells were cultured for an additional 18 hours with and without TGF-β or
BMP-4. Luciferase activities were assayed using the Dual-reporter assay kit
(Promega) and measured on a Monolight 2010 luminometer (Analytical Luminescence
Laboratory, Ann Arbor, MI). Experiments were performed in triplicate and repeated two
times. GAL4 reporter assay were performed as above with some modifications. Briefly,
DLX4 or empty vector was co-transfected with GAL4-driven reporter construct and
GAL4-DBD/Smad2 and GAL4-DBD/Smad3. TGF-β treatment and luciferase assays
were performed as described above.

8. Immunofluorescence staining

Cells (5x104/well) were seeded in 2-well chamber slides. Cells were serum
starved overnight and then treated with TGF-β for 1 hour. Cells were washed with PBS
and fixed with 1% paraformaldehyde (in PBS, pH 7.4) for 20 minutes on ice. Fixed
cells were washed with PBS two times and permeablized with 0.1% Triton X-100 (in
PBS) for 20 minutes on ice. Cells were then washed with PBS and blocked with 1%
goat serum in PBS for 30 minutes at 40C and stained with Abs to Smad2, DLX4, Ecadherin, or FLAG Ab (1:200). Cells were washed 5 times in PBS containing 1% BSA.
Staining was detected by Alexa Fluor 594-conjugated secondary Ab (1:1000). Cells
were also stained with 4',6-diamidino-2-phenylindole (DAPI) (1:1000) to visualize
nuclei.
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9. Immunoblotting

To determine protein expression levels, cells were lysed in M-PER buffer
(Pierce Biotechnology, Rockford, IL) according to the manufacturer’s instructions.
Total cell lysates were electrophoresed on 6 - 15% SDS gels, then transferred to
polyvinylidene difluoride (PVDF) membranes (Amersham Biosciences, Piscataway,
NJ) and blocked with 5% nonfat milk in PBS with 0.1% Tween-20 (PBS-T).
Immunoblotting was performed with primary Abs at recommended dilution provided by
manufacturers in PBS-T containing 5% nonfat milk except for phospho Smad2 Ab
which was prepared in PBS-T with 5% BSA. Membranes were hybridized with primary
Abs overnight at 4oC then washed with PBS-T buffer. Secondary Abs were diluted at
1:2000 in PBS-T with 5% nonfat milk and incubated with membranes for 1-2 hours at
room temperature. Membranes were then washed with PBS-T buffer and incubated
with ECL Western blotting detection reagent (Amersham Biosciences) and exposed to
autoradiographic film.

10. Immunoprecipitation

Cell lysate preparation:
Cells were plated to reach 70-80% confluence and were transfected with DLX4
or empty vector. At 24 hours after transfection, cells were serum-starved overnight and
then treated without or with 10 ng/ml TGF-β for 1 hour. To prepare whole cell lysates,
cells were washed with PBS buffer and lysed in native buffer (20 mM Tris-HCl pH 8.0,
100 mM NaCl, 1% NP-40, 10% glycerol, 2 mM EDTA) supplemented with protease
and phosphatase inhibitors for 10 minutes on ice. Cells were then sonicated. To

42

reduce viscosity caused by genomic DNA, benzonase enzyme was added. Lysates
were centrifuged at 12000 x g for 10 minutes and supernatants were collected. Whole
cell lysates were used immediately for immunoprecipitation or stored at -80oC. To
prepare nuclear extracts, cells were lysed in cytosol lysis buffer (10 mM HEPES pH
7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT plus protease and phosphatase inhibitors),
followed by centrifugation at 800 x g for 10 minutes. Nuclear pellets were washed then
lysed in native buffer (Tris pH 8.0 20mM, 100mM NaCl, NP40 1%, Glycerol 10% EDTA
2mM) plus protease and phosphatase inhibitors. The lysates were sonicated then
centrifuged at 12000 x g for 10 minutes. Supernatants were transferred to a fresh
eppendorf tube. Nuclear lysates were used immediately for immunoprecipitation or
stored at -80oC

Immunoprecipitation:
Whole cell extracts (1 mg) or nuclear extracts (500 ug) were pre-cleared with
protein G agarose (Amersham Biosciences) by rotating at 4°C for 30 minutes. Lysates
were then incubated with anti-FLAG-M2 affinity gel (Sigma-Aldrich) for 4-12 hours at
4°C. Where unconjugated primary Abs were used, lysates were incubated with the
Abs for 12 hours at 4°C then further incubated with protein G agarose for 1 hour at
4°C. Immunoprecipitates were washed five times with native buffer and subjected to
SDS PAGE and immunoblot analysis.
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11. Oligonucleotide pull-down assays

Preparation of biotinylated oligonucleotides:
Sense and antisense oligomers were designed to cover the p15Ink4B promotor
region from positions -108 to -39 (Figure 31A and Table 6). The sense oligomer was
labeled with biotin at the 5’ end. Oligos were generated by Sigma-Aldrich. Oligomers
were dissolved in H2O. Oligomers were annealed by incubating at 98oC for 10 minutes
followed by slow cooling down to room temperature overnight. The annealed product
was verified by agarose DNA electrophoresis.

DNA pull-down:
Nuclear lysates were prepared as described for immunoprecipitation except that
lysates were dissolved in binding buffer (10 mM HEPES pH 7.9; 100 mM KCl, 5 mM
MgCl2, 1 mM EDTA, 10% glycerol, 1 mM DTT, 0.5% NP-40) plus proteinase inhibitor
cocktail. Nuclear lysates were pre-cleared with strepavidin agarose for 30 minutes at
4°C. Biotin-labeled oligonucleotides were added to the lysate and incubated overnight
at 4°C with rotating. The lysate was then added to pre-washed streptavidin-conjugated
agarose beads and further rotated at 4°C for 1 hour. Beads were washed 4 times with
binding buffer. DNA bound proteins were eluted from strepavidin-conjugated agarose
beads with 1X SDS sample (Laemmli) buffer at 85°C for 5 minutes. The samples were
then subjected to SDS-PAGE and immunoblotting.
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Table 6. p15Ink4B oligomers for oligonucleotide pull-down assays

Name

Sequence

Sense strand

5'-BIOTINGCCTGGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGG
GGGTGGGGAGACGCCGGCCCCTTG-3’

Antisense strand

5'AAGGGGCCGGCGTCTCCCCACCCCCTTAGGCTCCGCCCCCTGTCCG
CTGTGATCGCCGGGAGGCCAGGC-3'
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12. In vitro binding assays
Preparation of GST fusion and 35S-labeled proteins:
GST fusion proteins containing full-length DLX4, truncated DLX4, Smad2 and
Smad4 were produced in E.coli and purified by glutathione beads (Amersham
Biosciences) following the manufacturer’s instructions.

35

S-labeled DLX4, Smad4 and

Sp1 were synthesized in vitro from the T7 promoter using the TNT coupled translation
kit (Promega) following the manufacturer’s instructions.

Binding assays:
GST fusion protein (1 µg) bound to glutathione-sepharose beads was preincubated with 0.5 mg/ml BSA in binding buffer (20 mM Tris [pH8.0], 100 mM NaCl,
0.1% NP40, 2 mM EDTA, plus proteinase inhibitor cocktail) for 1 hour.

35

S-labeled

proteins were pre-cleared by incubating with glutathione-sepharose beads in binding
buffer for 1 hour. GST fusion protein was then incubated with pre-cleared

35

S-labeled

protein for 2 hours. Beads were then extensively washed with binding buffer for 5
times. Associated proteins were subjected to SDS-PAGE and visualized by
autoradiography.

13. Total RNA extraction and qPCR

Total RNA extraction:
Total RNA was extracted using TRIzol reagent (Invitrogen) following
manufacturer’s instructions. Extracted RNA was treated with DNAseI and purified
using the RNeasy kit (Qiagen, Valencia, CA).

46

qPCR:
Purified total RNA (500 ng) was used to synthesize cDNA by random priming
using the RT² First Strand Kit (SABiosciences). cDNA and primers were included in a
reaction (20 ul) with the RT² SYBR® Green qPCR Master Mix (SABiosciences).
Reactions were run on the AB7500 system (Applied Biosystems, Carlsbad, CA) with
40 cycles of 950C for 15 seconds and 600C for 1 minute according to the standard
manufacturer’s program. Primers were predesigned to amplify a 98 bp region located
at positions 1278-1297 of the 3’ untranslated region of DLX4 gene (SABioscience).
Primer specificity was confirmed by including a dissociation curve at the end of thermal
cycles. Data analysis was performed using the delta-delta Ct method. Levels of DLX4
expression were normalized to β-actin.

14. Gel-shift assays

32

P-labeled probe preparation:
Oligomers were designed to contain sense and antisense sequences -88 to -64

of the p15Ink4B promoter with 5' overhangs for labeling (Figure 35A and Table 7).
Double-stranded oligos were generated by incubating sense and antisense oligomers
at 980C for 10 minutes followed by slow cooling to room temperature overnight.

32

P-

labeled probe was produced by end-filling using the Klenow enzyme (Roche Applied
Biosciences) following manufacturer’s instructions. The

32

P-labeled probe was then

purified through NICK™ Column (Amersham Biosciences) and eluted in TE buffer to a
final concentration of 1 ng/ul.
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Table 7. p15Ink4B oligomers for gel-shift assays

Name

Sequence

Sense strand

5'-CAGCGGACAGGGGGCGGAGCCTAAG-3’

Antisense strand

5'-CTTAGGCTCCGCCCCCTGT-3'
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Gel-shift reaction:
EMSA was performed in 25 µl reactions. Recombinant Sp1 protein (100 ng)
was incubated with increasing amounts of in vitro translated FLAG-DLX4 and FLAGtag synthesized from TNT coupled reticulocyte lysates (Promega) for 20 minutes in
binding buffer (10 mM Tris-HCl [pH 7.5], 1 mM MgCl2, 50 mM NaCl, 0.5 mM EDTA,
4% glycerol, 0.5 mM DTT, 1 µg poly(dI-dC).poly(dI-dC)) at 230C. 1ng of

32

P-labeled

probe was added to the binding reaction and incubated for an additional 20 minutes.
The reactions were electrophoresed on a 5% nondenaturing polyacrylamide gel. The
gel was dried and exposed to autographic film.

15. Chromatin immunoprecipitation

Chromatin immunoprecipitation (ChIP) was performed using the ChIP Assay Kit
(Upstate; Temecula, CA) following manufacturer’s instructions with modifications.
Briefly, cells were cross-linked by adding formaldehyde to 1% final concentration at
room temperature for 10 minutes. Formaldehyde was then quenched by adding
glycine and incubated at room temperature for 5 minutes. The cells were then washed
with PBS and scraped off dishes. Cell suspensions were centrifuged and the
supernatant was discarded. Cells were lysed in SDS lysis buffer containing protease
inhibitors and sonicated to generate DNA fragments of ~200-1000 base pairs in length.
Sheared chromatin was then pre-cleared with Protein G agarose then incubated with 4
ug of Abs to Sp1 (Zymed Laboratories), Smad4 (Cell signal), Smad2/3, and normal
IgG (Santa Cruz Biotechnology) overnight. Protein G agarose was then added and
incubated for 1 hour. The protein G agarose-antibody/chromatin complex was
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extensively washed, followed by elution of immunoprecipitated complexes and
reversal of cross-links. Protein and RNA were removed by incubating with RNase A
and proteinase K. Eluted DNA fragments were purified and used for PCR reactions to
amplify a 535 bp fragment of the p15Ink4B promoter (Table 8). The amplified fragment
was confirmed by DNA sequencing.
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Table 8. p15Ink4B primer sequences for ChIP PCR

Name

Sequence

Sense strand

5'-TATGGTTGACTAATTCAAACAG-3’

Antisense strand

5'-GCAAAGAATTCCGTTTTCAGCT-3'
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CHAPTER 3: DLX4 INHIBITS TGF-β-INDUCED, SMAD-DEPENDENT RESPONSES

A. RATIONALE

TGF-β inhibits growth of most types of normal cells by inducing cell cycle arrest.
The anti-proliferative effect of TGF-β is orchestrated by a cytostatic program of gene
responses that principally involves activation of the CDK inhibitors p15Ink4B and
p21WAF1/Cip1 (38, 51) and repression of the growth-promoting transcription factors c-myc
and Ids (52, 59) (Figure 6). In many types of tumors, the anti-proliferative effect of
TGF-β is abolished (3, 4). Resistance to the anti-proliferative effect of TGF-β has been
attributed to TGF-β receptor and/or Smad mutations in some types of tumors,
particularly those of gastrointestinal origin (112, 114, 115) (Table 2). However, the
rareness of these mutations in many other types of tumors indicates that resistance to
the anti-proliferative effect of TGF-β also stems from other aberrations (112) (Table 2).

Cross-talk between members of the DLX gene family and the TGF super-family
is important for controlling bone morphogenesis and skeletal patterning (1, 180, 181).
The homeobox gene DLX4 is not expressed in most normal adult tissues, but is
expressed in a wide range of tumors (Table 5). This raises the possibility that DLX4
promotes tumorigenesis via a mechanism common to multiple types of tumors. The
goal of my studies in this chapter is to determine whether DLX4 blocks TGF-β-induced,
Smad-dependent responses that are central to the anti-proliferative effect of TGF-β.
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B. RESULTS

1. DLX4 blocks TGF-β
β-mediated growth inhibition

To determine whether DLX4 blocks the anti-proliferative effect of TGF-β, we first
assayed the effect of DLX4 on cell growth in the non-tumorigenic lung epithelial cell
line Mv1Lu. Mv1Lu is a well-established model for studying TGF-β-induced growth
arrest (197, 198). Growth of Mv1Lu cells was inhibited by TGF-β in a dose-dependent
manner (Figure 14A). In contrast, enforced expression of DLX4 in Mv1Lu cells
decreased the sensitivity to TGF-β (Figure 14A). This observation indicates that DLX4
blocks the growth-inhibitory effect of TGF-β. To confirm this finding, the effect of
knocking-down DLX4 on cell growth was assayed. DLX4 was knocked-down by using
shRNAs that targeted different sites of DLX4 (sh90 and sh92). Knockdown of DLX4 in
MCF-7 breast cancer cells increased sensitivity to TGF-β in cell viability assays (Figure
14B). The ability of these shRNAs to knock-down DLX4 in MCF-7 cells was confirmed
by Western blot (Figure 15A) and also by qPCR and immunofluorescence staining
(Figure 15B, 15C).
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Figure 14. DLX4 blocks TGF-β
β-mediated growth inhibition
[A] Vector-control (-DLX4) and +DLX4 stable Mv1Lu lines were cultured with the
indicated concentrations of TGF-β for 2 days. Changes in cell growth were determined
by MTT assay, and expressed relative to growth of cells incubated without TGF-β.
Shown are results of two independent experiments each performed in triplicate. [B]
Transfected MCF-7 cells were cultured with the indicated concentrations of TGF-β for
2 days. Changes in cell growth were determined by MTT assay.
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Figure 15. Knockdown of DLX4
MCF-7 cells were transfected with empty vector, non-targeting shRNA and DLX4
shRNAs (sh90, sh92). [A] At 2 days after transfection, DLX4 levels were assayed by
Western blot. [B] DLX4 transcript levels in transfected MCF-7 cells were assayed by
qPCR using SYBR®Green qPCR Master Mix and DLX4 primers purchased from
SABiosciences. [C] At 2 days after transfection, endogenous DLX4 in cells was
detected by staining using DLX4 Ab (red). Nuclei were visualized by staining with
DAPI (blue). Bar, 20 µm.
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2. DLX4 blocks the ability of TGF-β
β to induce G1 arrest

TGF-β induces cell cycle arrest in G1 phase (198, 199). We determined whether
DLX4 blocks the ability of TGF-β to induce G1 arrest by performing cell cycle analysis.
Treatment of vector-control Mv1Lu cells with TGF-β led to significant accumulation of
cells in G1 phase (Figure 16A). However, enforced expression of DLX4 in Mv1Lu cells
inhibited the induction of G1 arrest by TGF-β (Figure 16A). Similarly, enforced
expression of DLX4 in the non-tumorigenic mammary epithelial cell line NMuMG also
inhibited TGF-β-induced G1 arrest (Figure 16B). Conversely, knockdown of DLX4 in
MCF-7 cells was observed to increase the proportion of cells in G1 phase (Figure
16C). These data indicate that DLX4 inhibits TGF-β-mediated G1 arrest.

3. DLX4 blocks Smad-dependent growth inhibition

TGF-β inhibits cell growth principally via Smad-dependent mechanisms that require
Smad4 (3). Because TGF-β can also inhibit cell growth via Smad-independent
mechanisms (60), we determined whether DLX4 blocks Smad-dependent growth
inhibition. The effect of DLX4 on cell growth was assayed using the MDA-MB-468
breast cancer cell line that has the homozygous deletion of Smad4 (122). Growth of
MDA-MB-468 cells was not inhibited by TGF-β (Figure 17). In contrast, reconstitution
of Smad4 in these cells increased responsiveness to TGF-β (Figure 17). This Smad4dependent responsiveness to TGF-β was abrogated when DLX4 was expressed
(Figure 17). These results confirm our finding that DLX4 opposes the anti-proliferative
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Figure 16. DLX4 blocks TGF-β
β-induced G1 arrest
[A] Mv1Lu lines were treated without and with 10 ng/ml TGF-β for 18 hours. [B]
Transfected MCF-7 cells were treated without and with TGF-β (10 ng/ml) for 18 hours.
[C] Vector-control (-DLX4) and +DLX4 NMuMG cells were treated without and with
TGF-β (5 ng/ml) for 18 hours. Indicated are the proportions of cells in G1, S and G2/M
phases determined by flow cytometric analysis of propidium iodide-staining.
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Figure 17. DLX4 blocks Smad-dependent growth inhibition
Vector-control (-DLX4) and +DLX4 stable MDA-MB-468 lines were transfected with
Smad4. At 24 hours thereafter, cells were cultured without and with TGF-β (10 ng/ml)
for 2 days and changes in cell growth were examined by MTT assay.
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effect of TGF-β, and indicate that DLX4 blocks TGF-β-mediated growth inhibition in a
Smad-dependent manner.

4. DLX4 inhibits gene responses of the TGF-β
β cytostatic program

TGF-β inhibits cell growth by controlling a cytostatic program of gene responses
that includes activation of p15Ink4B and p21WAF1/Cip1 transcription and repression of cmyc and Id transcription (38, 51, 52, 59). In subsequent experiments, we determined
whether DLX4 inhibits gene responses of this cytostatic program.

4.1. DLX4 inhibits TGF-β
β-mediated induction of CDK inhibitors

Treatment of vector-control Mv1Lu cells with TGF-β induced expression of p15Ink4B
(Figure 18A). However, enforced expression of DLX4 in Mv1Lu cells blocked TGF-βinduced p15Ink4B expression (Figure 18A). To determine whether this blocking effect
was Smad-dependent, we assayed the expression of TGF-β response genes in MDAMB-468 cells. Treatment of MDA-MB-468 cells with TGF-β did not induce expression
of p21WAF1/Cip1 (Figure 18B). When MDA-MB-468 cells were reconstituted with Smad4,
p21WAF1/Cip1 expression was induced by TGF-β. However, enforced expression of DLX4
blocked this induction (Figure 18B). These results indicate that DLX4 inhibits TGF-βmediated, Smad-dependent induction of CDK inhibitor expression.
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Figure 18. DLX4 blocks Smad-dependent cytostatic gene responses
[A] Western blot analysis of Mv1Lu lines following treatment without and with TGF-β
(10 ng/ml) for 16 hours. [B] Western blot analysis of MDA-MB-468 lines following
treatment without and with TGF-β for 16 hours.

61

4.2. DLX4 blocks Smad-dependent transcription of p15Ink4B

TGF-β induces transcription of p15Ink4B and p21WAF1/Cip1 by similar Smaddependent mechanisms (38, 51). Because DLX4 is a transcription factor, it is likely
that DLX4 blocks Smad-mediated transcription of these genes. To investigate this
possibility, we focused on the well-characterized p15Ink4B promoter. The first 113 bp of
the p15Ink4B promoter are essential for induction by TGF-β and contain two Smadbinding elements (SBEs) (51). We initially determined whether DLX4 inhibits the ability
of TGF-β to induce p15Ink4B promoter activity by reporter assays using a construct
driven by the minimal p15Ink4B promoter (-113 to +70) (p15-WT). Activity of this minimal
promoter was induced by TGF-β in vector-control Mv1Lu cells, and this induction was
abolished by mutation of the SBEs (Figure 19A). Enforced expression of DLX4 in
Mv1Lu cells abolished the induction of wild-type p15Ink4B promoter activity by TGF-β
(Figure 19A). DLX4 also modestly inhibited activity of the SBE-mutant promoter
(Figure 19A). This result suggests that DLX4 also can block basal p15Ink4B promoter
activity independently of TGF-β/Smad signaling. To confirm that DLX4 blocks Smadmediated induction of p15Ink4B, we assayed p15Ink4B promoter activity in Smad4deficient MDA-MB-468 cells. Wild-type p15Ink4B promoter activity was unresponsive to
TGF-β in MDA-MB-468 cells. TGF-β responsiveness was conferred when Smad4 was
expressed in these cells. However, this Smad4-dependent responsiveness was
eliminated when DLX4 was co-expressed (Figure 19B). Together, these findings
demonstrate that DLX4 blocks Smad-mediated transcription of p15Ink4B.
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Figure 19. DLX4 inhibits TGF-β
β-mediated induction of p15Ink4B promoter activity
[A] Mv1Lu cells were co-transfected with empty vector (grey bar) or DLX4 (black bar),
together with reporter plasmids containing no promoter (pGL2 vector), p15Ink4B
promoter sequences (-113 to +70) (p15-WT), and p15Ink4B promoter with mutated
SBEs (p15-SBE-mt). Cells were cultured without and with TGF-β for 18 hours, and
assayed for F-Luc activity. [B] Reporter assays using the p15-WT reporter plasmid
were performed using transfected MDA-MB-468 lines. Shown are relative F-Luc
activities in three independent experiments each performed in duplicate. Values were
normalized by activity of co-transfected R-Luc.
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4.3. DLX4 induces c-myc expression independently of TGF-β
β/Smad signaling

In subsequent experiments, we determined whether DLX4 blocks TGF-βmediated repression of c-myc expression. Enforced expression of DLX4 induced cmyc expression in MDA-MB-468 cells, irrespective of the absence or presence of
Smad4 (Figure 18B). Because DLX4 induced the level of c-myc protein independently
of TGF-β/Smad signaling, we investigated the effect of DLX4 on c-myc induction by
assaying c-myc promoter activity. Activity of the c-myc promoter was repressed by
TGF-β in vector-control Mv1Lu cells (Figure 20A). However, enforced expression of
DLX4 in Mv1Lu cells induced c-myc promoter activity both in the absence and
presence of TGF-β stimulation (Figure 20A). In converse experiments, knock-down of
DLX4 inhibited c-myc promoter activity in MCF-7 cells in the absence of TGF-β
stimulation (Figure 20B). TGF-β treatment of DLX4 knock-down cells further inhibited
c-myc promoter activity (Figure 20B). These results suggest that DLX4 blocks the
ability of TGF-β to repress c-myc expression and can also induce c-myc expression
independently of TGF-β/Smad signaling.
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Figure 20. DLX4 induces c-myc promoter activity
[A] Mv1Lu cells were co-transfected with empty vector (grey bar) or DLX4 (black bar),
together with empty pBV-Luc vector or with pBV-MYC(Del4) reporter plasmid that
contains 900 bp of c-myc P1 and P2 promoter sequences. Transfected cells were
cultured without and with TGF-β (10 ng/ml) for 18 hours, and assayed for F-Luc
activity. [B] Reporter assays for c-myc promoter activity were likewise conducted using
MCF-7 cells that were co-transfected with non-targeting shRNA (grey bar) and DLX4
(sh90) shRNA (black bar).
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5. DLX4 inhibits TGF-β
β -induced EMT

In addition to its anti-proliferative effect, TGF-β is well-known to induce EMT via
Smad and non-Smad mechanisms (3, 4) (Figure 8). Because our results demonstrate
that DLX4 blocks TGF-β-mediated growth inhibition in a Smad-dependent manner, it is
possible that DLX4 also blocks the ability of TGF-β to induce EMT. To address this
possibility, we used the NMuMG cell line, a well-established model for studying TGF-βinduced EMT. Smad4 has been demonstrated to be essential for TGF-β-induced EMT
in several cell types, including NMuMG cells (200). TGF-β treatment of vector-control
NMuMG cells induced profound epithelial-to-fibroblastic morphologic transformation
(Figure 21A). E-cadherin expression was lost, whereas N-cadherin was induced in
vector-control NMuMG cells following TGF-β treatment (Figures 21B, 21C). In contrast,
enforced expression of DLX4 in NMuMG cells blocked the down-regulation of Ecadherin and induction of N-cadherin (Figures 21B, 21C). Additionally, epithelial
morphology was considerably retained in TGF-β-treated +DLX4 NMuMG cells (Figure
21A). These results indicate that DLX4 can inhibit TGF-β-induced EMT.
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Figure 21. Effect of DLX4 on TGF-β
β-induced EMT
Vector-control (-DLX4) and +DLX4 NMuMG cells were incubated without or with TGFβ (5 ng/ml) for 24 hours. [A] Morphology of cells was visualized by phase-contrast
microscopy.

Bar,
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µm.

[B]

E-cadherin

expression

was

detected

by

immunofluorescence staining (red). Nuclei were visualized by staining with DAPI
(blue). Bar, 20 µm. [C] Western blot analysis of DLX4, E-cadherin and N-cadherin.

67

68

C. CONCLUSION

The studies in this chapter demonstrate that DLX4 blocks the anti-proliferative
effect of TGF-β by inhibiting the TGF-β-mediated cytostatic program of gene
responses that cause G1 arrest. The studies demonstrate that DLX4 blocks the ability
of TGF-β to induce p15Ink4B and p21WAF1/Cip1 expression, and that this blocking effect
occurs via Smad-dependent mechanisms. In addition, the studies demonstrate that
DLX4 blocks the ability of TGF-β to repress c-myc expression, and can also induce cmyc expression independently of TGF-β/Smad signaling. Furthermore, our findings
indicate that DLX4 blocks the ability of TGF-β to induce EMT in cells that normally
undergo TGF-β-induced EMT in a Smad-dependent manner. Together, our findings
that DLX4 blocks TGF-β-mediated, Smad-dependent growth inhibition and also EMT
indicate that DLX4 inhibits a core component of the TGF-β/Smad signaling pathway.
Identification and characterization of this inhibitory mechanism will be the focus of
Chapter 4 and Chapter 5.
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CHAPTER 4: DLX4 BLOCKS SMAD TRANSCRIPTIONAL ACTIVITY

A. RATIONALE

Binding of TGF-β to TβRII leads to recruitment and activation of TβRI which in
turn phosphorylates R-Smads. Phosphorylated R-Smads translocate to the nucleus,
where they form heteromeric complexes with Smad4 and other DNA-binding factors to
regulate gene transcription (9, 12) (Figure 2). TGF-β/Smad signaling is modulated at
multiple levels. These include binding of TGF-β to TβRII, formation of the TβRI-TβRII
complex, phosphorylation and nuclear localization of R-Smads, and transcriptional
activity of Smad proteins (Figure 2).

Studies in Chapter 3 demonstrated that DLX4 blocks TGF-β-mediated gene
responses through Smad-dependent mechanisms. Because DLX4 is a transcription
factor, we hypothesize that DLX4 blocks TGF-β signaling by interfering with Smad
transcriptional activity. The goal of the studies in this chapter is to determine whether
and how DLX4 blocks Smad activity.
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B. RESULTS

1. DLX4 does not affect phosphorylation, expression and localization of RSmads

As discussed in Chapter 1, Smad-dependent transcription is controlled at
multiple levels, including phosphorylation, expression and nuclear localization of Smad
proteins (201). Enforced expression of DLX4 in Mv1Lu cells did not alter the
expression level of Smad2 (Figure 22A). The expression levels of Smad3 and Smad4
were also not affected by DLX4 (see Figure 27B, discussed later). Furthermore, DLX4
did not affect TGF-β-induced phosphorylation of Smad2 (Figure 22A). This result also
implies that DLX4 has no effect on activation of TGF-β receptors. Treatment of vectorcontrol cells with TGF-β induced rapid translocation of Smad2 from the cytoplasm to
the nucleus (Figure 22B). Enforced expression of DLX4 did not interfere with this
translocation of Smad2 (Figure 22B). We also investigated whether TGF-β stimulation
affected the localization of DLX4. Immunofluorescence staining studies demonstrated
that DLX4 is predominantly localized in the nucleus and that its nuclear localization is
not affected by TGF-β stimulation (Figures 22C, 22D). These findings indicate that
DLX4 most likely inhibits nuclear events downstream of the TGF-β signaling pathway.
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Figure 22. Phosphorylation, expression levels and localization of Smad and
DLX4 proteins
Vector-control (-DLX4) and +DLX4 Mv1Lu lines were serum-starved overnight and
then treated without and with TGF-β (10 ng/ml) for 30 minutes. [A] Total and
phosphorylated Smad2 were detected by Western blot. [B] Intracellular localization of
Smad2 was detected by immunofluorescence staining. Bar, 20 µm. [C] MvL1Lu cells
that stably express FLAG-DLX4 were serum-starved overnight, and then incubated in
complete medium for 30 minutes without or with TGF-β (10 ng/ml). Following fixation
and permeabilization, cells were stained with FLAG Ab (red). [D] Parental MCF-7 cells
were treated as in [C]. Endogenous DLX4 in cells was detected by staining using
DLX4 Ab (red). Nuclei were visualized by staining with DAPI (blue). Bar, 20 µm.
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2. DLX4 blocks transcriptional activity of activated R-Smads

Smad proteins contain two functional domains with an intervening linker region.
MH1 domains are responsible for binding to SBEs, whereas MH2 domains mediate
interactions of Smads with one another and with other transcription factors (8, 12)
(Figure 3). MH2 domains of Smad2 and Smad3 have intrinsic transcriptional activation
capacity (8). We, therefore, sought to determine whether DLX4 inhibits transcriptional
activity of Smad2 and Smad3 (Figure 23).

2.1. DLX4 represses transcriptional activity of Smad2

A chimeric expression construct was generated by fusing the GAL4 DNAbinding domain (DBD) to the linker region and MH2 transcriptional activation domain of
Smad2 [amino acids 173 to 467]. To determine whether DLX4 represses
transcriptional activity of Smad2, the GAL4-DBD/Smad2 chimera was co-expressed in
Mv1Lu cells along with a firefly luciferase (F-Luc) reporter controlled by a synthetic
promoter comprising five tandem GAL4 binding sites. As shown in Figure 24A,
transcriptional activity of GAL4-Smad2 was induced by TGF-β in the absence of DLX4.
However, this activation was abolished when DLX4 was expressed (Figure 24A).
Similar results were obtained using the hepatoma cell line HepG2, which is responsive
to TGF-β (Figure 24A). In converse experiments, we observed that knockdown of
DLX4 in MCF-7 cells increased TGF-β-mediated induction of GAL4-Smad2 activity
(Figures 24B).
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Figure 23. Schematic design of GAL4-Smad2/3 chimeras and reporter assay
Chimeras were constructed in which the linker and MH2 domains of Smad2 and
Smad3 were fused to the GAL4-DBD. These chimeras were tested for their ability to
induce a synthetic promoter containing GAL4 binding element (GAL4BE).

75

Figure 24. DLX4 blocks Smad2 transcriptional activity
[A] Mv1Lu and HepG2 cells were co-transfected with empty vector (grey bar) or DLX4
(black bar), together with GAL4-driven F-Luc reporter plasmid and with GAL4-Smad2.
Transfected cells were cultured without and with TGF-β for 18 hours, and assayed for
F-Luc activity. [B] GAL4-Smad2 activity were likewise assayed in MCF-7 cells that
were co-transfected with non-targeting shRNA (grey bar) or DLX4 (sh90) shRNA
(black bar).
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2.2. DLX4 represses transcriptional activity of Smad3

We also investigated the effect of DLX4 on transcriptional activity of Smad3 by
generating a chimeric construct in which the GAL4-DBD was fused to the linker region
and MH2 transcriptional activation domain of Smad3 [amino acids 133 to 425]. As
observed with our assays using the GAL4-Smad2 chimera, we found that DLX4
similarly abolished TGF-β-induced transcriptional activity of the GAL4-Smad3 chimera
in both Mv1Lu and HepG2 cells (Figure 25A). Conversely, knockdown of DLX4 in
MCF-7 cells enhanced TGF-β-mediated induction of GAL4-Smad3 activity (Figure
25B).

2.3. DLX4 blocks gene transcription mediated by BMP-activated R-Smads

Smad2 and Smad3 serve as substrates for the TβRI kinase and are activated
by TGF-β, whereas other R-Smads (Smads 1, 5 and 8) are utilized by the BMP and
anti-Müllerian receptors (10, 201). We initially tested the ability of DLX4 to inhibit
transcription induced by other members of the TGF super-family by using a synthetic
promoter comprising four tandem SBEs (pSBE4-Luc). Activity of this promoter was
induced by TGF-β treatment of vector-control HepG2 cells (Figure 26A). This induction
was blocked by DLX4. Similarly, BMP-4 treatment of HepG2 cells induced activity of
the SBE-driven promoter, whereas DLX4 blocked BMP-4-mediated induction of the
promoter (Figure 26A). TGF-β- and BMP-specific R-Smads have been reported to
preferentially bind distinct DNA sequences (196, 202). Indeed, we found that BMP-4
was not as effective as TGF-β in inducing pSBE4-Luc activity (Figure 26A). We,
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Figure 25. DLX4 blocks Smad3 transcriptional activity
[A] Mv1Lu and HepG2 cells were co-transfected with empty vector (grey bar) or DLX4
(black bar), together with GAL4-driven F-Luc reporter plasmid and with GAL4-Smad3.
Transfected cells were cultured without and with TGF-β for 18 hours, and assayed for
F-Luc activity. [B] GAL4-Smad3 activities were, likewise, assayed in MCF-7 cells that
were co-transfected with non-targeting shRNA (grey bar) or DLX4 (sh90) shRNA
(black bar).
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therefore, tested the effect of DLX4 on BMP-induced transcription by using a reporter
plasmid that contains the BMP-responsive promoter of the Id1 gene. BMP-4 induced
Id1 promoter activity in vector-control HepG2 cells, whereas expression of DLX4
blocked BMP-induced Id1 promoter activity (Figure 26B). To confirm this blocking
effect of DLX4, we used a synthetic promoter comprising two tandem copies of the
BMP response elements of the Id1 promoter (BRE-Luc). Activity of this promoter was
induced by BMP-4 treatment of vector-control HepG2 cells. However, BMP-4-induced
activation of the promoter was blocked when DLX4 was expressed (Figure 26C).
Because TGF-β- and BMP-specific R-Smads utilize Smad4 as the common and
essential partner for the formation of functional transcriptional complexes (201), our
findings raise the possibility that DLX4 inhibits Smad4.
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Figure 26. Effect of DLX4 on TGF-β
β and BMP-induced transcription
[A] HepG2 cells were co-transfected with empty vector (grey bar) or DLX4 (black bar)
together with SBE-driven pSBE4-Luc reporter plasmid, and then cultured without and
with TGF-β (10ng/ml) or BMP-4 (80 ng/ml) for 18 hours. [B] HepG2 cells were cotransfected with empty vector (grey bar) or DLX4 (black bar), together with reporter
plasmids containing no promoter (pGL2 vector) or a 1.6 kb region of the Id1 promoter.
At 24 hours after transfection, cells were cultured without and with BMP-4 (80 ng/ml)
for additional 18 hours. [C] HepG2 cells were co-transfected with empty vector (grey
bar) or DLX4 (black bar) together with BRE-Luc reporter plasmid, and then cultured
without and with BMP-4 (80 ng/ml) for 18 hours. Shown are relative F-Luc activities in
three independent experiments each performed in duplicate and normalized by activity
of co-transfected R-Luc.
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3. DLX4 prevents Smad4 from binding R-Smads

The formation of R-Smad/Smad4 transcriptional complexes is essential for
Smad-mediated transcription (10, 12). In subsequent experiments, we determined
whether DLX4 interferes with the binding of Smad4 to R-Smads. Following transfection
with FLAG-tagged DLX4 or empty vector, HepG2 cells were treated with or without
TGF-β. Smad2 was immunoprecipitated, and precipitates were analyzed by
immunoblotting using Ab to Smad4. Binding of Smad4 to Smad2 was observed
following TGF-β treatment. However, this interaction was inhibited when DLX4 was
expressed

(Figure

27A).

Identical

results

were

obtained

in

reciprocal

immunoprecipitation (IP) assays in which Smad4 was immunoprecipitated and Smad2
was detected in precipitates (Figure 27A).

Because Smad2 and Smad3 are highly homologous and they both interact with
Smad4 via their MH2 domains (8, 203), we determined whether DLX4 also interferes
with interaction of Smad3 and Smad4. As shown in Figure 27A, treatment of vectorcontrol HepG2 cells with TGF-β induced binding of Smad4 to Smad3. In contrast, this
binding was inhibited when DLX4 was expressed. DLX4 did not alter expression levels
of Smad2, Smad3 or Smad4 (Figure 27B). Together, these results indicate that DLX4
likely inhibits transcriptional activity of Smad2 and Smad3 by preventing Smad4 from
interacting with these R-Smads.
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Figure 27. DLX4 prevents Smad4 from binding R-Smads
HepG2 cells were transfected with empty vector or with FLAG-tagged DLX4. At 24
hours thereafter, cells were serum-starved overnight and then treated without and with
TGF-β (10ng/ml) for 30 minutes. [A] Smad2 was immunoprecipitated from nuclear
extracts and precipitates were analyzed by immunoblotting using Ab to Smad4.
Conversely, Smad4 was pulled-down and precipitates analyzed by immunoblotting
using Smad2 Ab. Because HepG2 cells express low levels of Smad3, IP assays to
detect binding of Smad3 to Smad4 were performed using extracts of cells that had
been transfected with Smad3. [B] Western blot of DLX4 and Smad proteins in nuclear
extracts.
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4. DLX4 interacts with Smad4

Our findings that DLX4 prevents Smad4 from interacting with R-Smads raise
the possibility that DLX4 binds Smad4. In subsequent experiments, we determined
whether DLX4 interacts with Smad4 and whether this interaction involves direct
binding.

4.1. DLX4 directly binds Smad4

To initially investigate whether DLX4 associates with Smad4 in cells, IP assays
were performed using extracts of HepG2 cells that expressed FLAG-DLX4 or empty
vector. We found that FLAG-tagged DLX4 associated with Smad4, irrespective of
TGF-β stimulation (Figure 28A). We next determined whether endogenous DLX4 could
interact with Smad4. Endogenous DLX4 was immunoprecipitated by DLX4 Ab from
lysates of MCF-7 cells, and Smad4 was detected in precipitates. IP of normal IgG was
included as a negative control (Figure 28B). To additionally confirm the interaction of
DLX4 with Smad4, we performed IP using extracts of MCF-7 cells that had been
transfected with DLX4 shRNA (sh90) or with non-targeting shRNA. As shown in Figure
28B, the interaction of DLX4 with Smad4 was reduced when DLX4 was knockeddown. To determine whether DLX4 interacts with Smad4 by direct binding, we tested
the ability of in vitro-translated

35

S-labeled DLX4 to bind GST-Smad4 protein. GST-

pulldown assays demonstrated that DLX4 directly binds Smad4 (Figure 28C). DLX4
also bound Smad2, but this binding was weaker than binding to Smad4 (Figure 28C).
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Figure 28. DLX4 binds to Smad4
[A] HepG2 cells were transfected with empty vector or with FLAG-tagged DLX4. At 24
hours thereafter, cells were serum-starved overnight and then treated without and with
TGF-β (10ng/ml) for 30 min. FLAG-DLX4 was immunoprecipitated using FLAG Ab,
and precipitates analyzed by immunoblotting using Ab to Smad4. Conversely, FLAGDLX4 was detected in precipitates following IP using Smad4 Ab. [B] MCF-7 cells were
transfected with non-targeting shRNA or with DLX4 (sh90) shRNA. Endogenous DLX4
was immunoprecipitated using DLX4 Ab, and precipitates analyzed by immunoblotting
using Smad4 Ab. IP using mouse IgG was included as a negative control. [C]
Expression of GST-Smad2 and GST-Smad4 proteins was confirmed by SDS-PAGE
(left). GST-fusion proteins were assayed for direct binding to in vitro translated
labeled full-length DLX4 (right).
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4.2. Identification of binding domains of DLX4 and Smad4

We sought to identify the Smad4-binding domain of DLX4 by testing truncated
GST-DLX4 fusion proteins for their ability to bind in vitro-translated

35

S-labeled full-

length Smad4 (Figure 29A). We generated GST-DLX4 fusion proteins that contained
full-length DLX4 (FL), only the homeodomain (HD), only the transactivation domain
(TA), and the transactivation domain and homeodomain but lacking the C-terminal tail
(TA+HD) (Figure 29B). Deletion of the C-terminal tail of DLX4 (TA+HD) only weakly
affected its ability to bind Smad4 (Figure 29C). In contrast, deletion of the DNA-binding
homeodomain of DLX4 markedly inhibited its Smad4-binding ability (TA). Binding of
the DLX4 homeodomain to Smad4 (HD) was detected but not as strongly as observed
with full-length DLX4 (Figure 29C).

We also investigated which domain of Smad4 interacts with DLX4 by testing the
ability of GST-DLX4 protein to bind in vitro-translated portions of Smad4 protein
(Figure 30A). We generated in vitro-translated proteins that contained full-length
Smad4 (FL), only the MH1 domain (MH1), only the MH2 domain (MH2), and the MH1
and MH2 domains with the linker region (MH1+LK, LK+MH2) (Figure 30A). Direct
binding of DLX4 was detected to the Smad4 MH1 domain alone, but not to the MH2
domain (Figure 30C).
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Figure 29. DLX4 binds to Smad4 in part via the homeodomain
[A] GST-DLX4 constructs comprising the transactivation domain (TA), homeodomain
(HD) and C-terminal tail (C). [B] Full-length (FL) DLX4 and portions thereof were
expressed as GST-fusion proteins, and [C] assayed for binding to
length Smad4.
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35

S-labeled full-
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Figure 30. DLX4 binds to the MH1 domain of Smad4
[A] Smad4 constructs comprising MH1 and MH2 domains and linker (LK) region. [B]
35

S-labeled full-length and truncated Smad4 were translated in vitro and [C] assayed

for binding to full-length GST-DLX4 protein.
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5. DLX4 blocks interaction of Smad proteins with DNA

Smad proteins bind to SBEs via their MH1 domains (33). Because DLX4 binds
to the MH1 domain of Smad4, we investigated whether DLX4 blocks the interaction of
Smad proteins to DNA. This was initially investigated by in vitro DNA pull-down
assays. A biotinylated oligonucleotide containing sequences of the minimal p15Ink4B
promoter region (nucleotides -108 to -39), including the SBEs (Figure 31A), was used
to pull-down Smad proteins from nuclear extracts. Increased levels of Smad2 and
Smad4 were detected in DNA-protein complexes when vector-control HepG2 cells
were stimulated with TGF-β (Figure 31B). In contrast, these increased levels of Smad
interactions with DNA were not observed when DLX4 was expressed (Figure 31B).

To confirm the ability of DLX4 to block Smad-DNA interactions in a more
physiological context, we performed ChIP assays. As shown in Figure 31C,
association of Smad4 and R-Smads with the p15Ink4B promoter was detected by ChIP
assays in vector-control HepG2 cells following TGF-β treatment. In contrast,
interactions of Smad proteins with the p15Ink4B promoter were abrogated when DLX4
was expressed (Figure 31C).
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Figure 31. DLX4 blocks interactions of Smad proteins with the p15Ink4B promoter
[A] Sequence of the minimal p15Ink4B promoter indicating Sp1 binding sites and SBEs
(adapted from (51)). Underlined are sequences contained in the oligonucleotides used
for oligonucleotide pull-down assays (solid line) and gel-shift assays (dashed line).
[B] Biotinylated oligonucleotide containing sequences -108 to -39 of the p15Ink4B
promoter was incubated with HepG2 nuclear extracts and pulled-down. DNA-bound
proteins in precipitates were analyzed by immunoblotting. [C] ChIP analysis of
interactions of Smad and Sp1 proteins with the p15Ink4B promoter. The input fraction
corresponded to 1 % of the chromatin solution of each sample before IP.
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C. CONCLUSION

The studies in this chapter provide significant insight into the mechanism by
which DLX4 blocks TGF-β/Smad signaling. Firstly, we demonstrate that DLX4 does
not alter phosphorylation, expression and nuclear localization of Smad proteins but
that DLX4 blocks TGF-β-induced transcriptional activity of Smad2 and Smad3. Our
observation that DLX4 prevents Smad4 from binding to R-Smads suggests that DLX4
inhibits the formation of R-Smad/Smad4 transcriptional complexes. We also
demonstrate that DLX4 directly binds to the MH1 domain of Smad4, and that binding
of DLX4 to Smad4 is mediated in part via its homeodomain. Direct binding of DLX4 to
Smad4 and the ability of DLX4 to also block BMP-induced transcription suggests that
DLX4 could block signaling induced by different ligands of the TGF super-family that
all utilize Smad4. In addition to the binding of Smad transcriptional complexes to
SBEs, the interaction of Smad proteins with other transcription factors dictates the
specificity and affinity of Smad complexes for target gene promoters. Understanding
the interactions of Smads with other transcription factors will be the focus of Chapter 5.
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CHAPTER 5: DLX4 REPRESSES SMAD/SP1-MEDIATED TRANSCRIPTION

A. RATIONALE

Both the strength and specificity of Smad-mediated transcription are governed
by interactions of Smad complexes with specific transcriptional factors and their
interactions with corresponding DNA-binding elements on target promoters (8, 10, 35)
(Figures 4, 5). Transcriptional activation of genes encoding the CDK inhibitors p15Ink4B
and p21WAF1/Cip1 is mediated by cooperative interactions between Sp1 and Smads that
bind to GC boxes and SBEs respectively on the p15Ink4B and p21WAF1/Cip1 promoters
(36, 38, 51).

In Chapters 3 and 4, we determined that DLX4 blocks Smad-mediated induction
of p15Ink4B and p21WAF1/Cip1. We found that DLX4 binds to Smad4, and blocks the
interaction of Smad4 with R-Smads, and also the interactions of Smad complexes with
DNA. Because cooperative interactions between Sp1 and Smads are important for
Smad-mediated transcription of the CDK inhibitor genes, we hypothesize that DLX4
could interfere with Smad-Sp1 interactions. The goal of the studies in this chapter is to
determine whether and how DLX4 modulates Smad-Sp1-mediated transcription.
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B. RESULTS

1. DLX4 does not prevent interactions of Smad4 and Sp1 proteins

TGF-β-induced transcription of p15Ink4B and p21WAF1/Cip1 requires cooperative
interactions between Sp1 and Smads proteins, in particular, Smad4, (37, 38, 51). In
initial experiments, we investigated whether DLX4 interferes with the interaction of
Smad4 with Sp1 by IP assays. Following transfection with FLAG-tagged DLX4 or
empty vector, HepG2 cells were treated with or without TGF-β. Sp1 was
immunoprecipitated, and precipitates were analyzed by immunoblotting using Ab to
Smad4. As reported in other studies (51), we similarly observed binding of Smad4 to
Sp1 following TGF-β treatment of vector-control cells. Surprisingly, we observed
interaction of Smad4 with Sp1 in cells that expressed DLX4, even in the absence of
TGF-β stimulation (Figure 32A). These observations were confirmed in reciprocal IP
assays in which Smad4 was immunoprecipitated and Sp1 was assayed in precipitates
(Figure 32A). DLX4 did not alter the expression levels of Sp1 and Smad4 (Figure
32B). This finding indicates that DLX4 facilitates interaction between Smad4 and Sp1
independently of TGF-β stimulation.

94

Figure 32. DLX4 facilitates interactions of Smad4 and Sp1
HepG2 cells were transfected with empty vector or with FLAG-tagged DLX4. At 24
hours thereafter, cells were serum-starved overnight and then treated without and with
TGF-β (10 ng/ml) for 30 minutes. [A] Sp1 was immunoprecipitated from nuclear
extracts and precipitates analyzed by immunoblotting using Ab to Smad4. Conversely,
Smad4 was pulled-down and precipitates analyzed by immunoblotting using Sp1 Ab.
[B] Western blot of DLX4 and Smad4 and Sp1 in nuclear extracts.
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2. DLX4 interacts with Sp1

In Smad/Sp1 transcriptional complexes, Sp1 directly binds Smad4 (51).
Because we previously found that DLX4 directly binds Smad4, it is possible that DLX4
also interacts with Sp1. In subsequent experiments, we determined i) whether DLX4
interacts with Sp1, ii) whether this interaction involves direct binding, and iii) what are
the binding domains of Sp1 and DLX4.

2.1. DLX4 directly binds Sp1

We first determined whether DLX4 interacts with Sp1 in cells. IP assays were
performed using extracts of HepG2 cells that expressed FLAG-DLX4 or empty vector.
FLAG-tagged DLX4 associated with Sp1, irrespective of TGF-β stimulation (Figure
33A). We next determined whether endogenous DLX4 interacts with Sp1. Endogenous
DLX4 was immunoprecipitated by DLX4 Ab from lysates of MCF-7 cells, and Sp1 was
detected in precipitates. IP of normal IgG was included as a negative control (Figure
33B). To confirm the interaction of DLX4 with Sp1, we performed IP using lysates of
MCF-7 cells that had been transfected with DLX4 shRNA (sh90) or with non-targeting
shRNA. As shown in Figure 33B, the interaction of DLX4 with Sp1 was reduced when
DLX4 was knocked-down.

To determine whether DLX4 directly binds Sp1, we performed GST-pulldown
assays. Full-length GST-DLX4 fusion protein (FL) directly bound to in vitro-translated
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Figure 33. DLX4 associates with Sp1
[A] Lysates were prepared from HepG2 cells as described in Figure 32A. Interaction of
FLAG-DLX4 with Sp1 was detected by reciprocal IP using FLAG and Sp1 Abs. [B]
MCF-7 cells were transfected with non-targeting shRNA or with DLX4 (sh90) shRNA.
Endogenous DLX4 was immunoprecipitated using DLX4 Ab, and precipitates analyzed
by immunoblotting using Sp1 Ab. IP using mouse IgG was included as a negative
control.
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35

S-labeled full-length Sp1 (Figure 34A). Similarly, full-length GST-Sp1 fusion protein

was observed to bind in vitro-translated 35S-labeled DLX4 (Figure 34C).

2.2. Identification of binding domains of DLX4 and Sp1

We determined the domain of DLX4 that binds to Sp1 by performing GST pulldown assays using GST-DLX4 fusion proteins that contained different domains of
DLX4 (Figure 29A, B). Binding of the homeodomain of DLX4 to in vitro-translated Sp1
was strongly detected (Figure 34A). This binding was comparable to binding of fulllength DLX4 to Sp1. Deletion of the C-terminal tail or the transactivation domain of
DLX4 did not affect its ability to bind Sp1 (Figure 34A).

In converse experiments, we determined the domain of Sp1 that binds DLX4.
Sp1 comprises a C-terminal DNA-binding domain [amino acids 557 to 778] and an Nterminal transactivation domain [amino acids 1 to 557] (Figure 34B). We generated in
vitro-translated

35

S-labeled proteins that contained full-length Sp1 (FL), the DNA-

binding domain of Sp1 (DBD) and its transactivation domain (TA) (Figure 34C). DLX4
did not bind the transactivation domain of Sp1, but bound to its DNA-binding domain
(Figure 34C). Together, these findings demonstrate that the interaction between DLX4
and Sp1 is mediated via their respective DNA-binding domains.
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Figure 34. DLX4 binds to the DNA-binding domain of Sp1
[A] GST-DLX4 proteins (described in Figure 29A) were assayed for binding to

35

S-

labeled full-length Sp1. [B] Sp1 constructs comprising the transactivation domain (TA)
and DNA-binding domain (DBD). [C]

35

S-labeled full-length (FL) and truncated Sp1

were translated in vitro (left) and assayed for binding to full-length GST-DLX4 protein
(right).
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3. DLX4 inhibits DNA-binding activity of Sp1

3.1. DLX4 blocks interactions of Sp1 with the p15Ink4B promoter

Because DLX4 binds the DNA-binding domain of Sp1, it is possible that DLX4
interferes with the DNA-binding ability of Sp1. To determine whether DLX4 alters the
binding of Sp1 to its recognition element, we performed in vitro DNA pull-down assays
using a biotinylated oligonucleotide containing sequences of the minimal p15Ink4B
promoter region (nucleotides -108 to -39). This contains two GC boxes plus two SBEs
(Figure 35A). In contrast to Smad proteins, binding of Sp1 to this promoter was
detected in lysates of vector-control HepG2 cells in the absence of TGF-β stimulation
(Figure 35B). TGF-β stimulation increased the level of DNA-bound Sp1 in vectorcontrol cells (Figure 35B). However, very little DNA-bound Sp1 was detected in lysates
of HepG2 cells that expressed DLX4, irrespective of TGF-β stimulation (Figure 35B).

To confirm this finding in a more physiological context, ChIP was performed to
assay binding of endogenous Sp1 to the p15Ink4B promoter. As shown in Figure 35C,
association of Sp1 with the p15Ink4B promoter was detected in vector-control HepG2
cells following TGF-β treatment. In contrast, binding of Sp1 to the p15Ink4B promoter
was not detected in cells that expressed DLX4, irrespective of TGF-β stimulation
(Figure 35C). The ability of DLX4 to block binding of Sp1 to the p15Ink4B promoter is
similar to its ability to block DNA-binding of Smad proteins as we demonstrated in
Chapter 4. Together, these findings indicate that DLX4 blocks the interaction of
Smad/Sp1 complexes with target gene promoters.

100

Figure 35. DLX4 blocks interactions of Sp1 protein with the p15Ink4B promoter
[A] Sequence of the minimal p15Ink4B promoter indicating Sp1 binding sites and SBEs
(adapted from (51)). Underlined are sequences contained in the oligonucleotides used
for oligonucleotide pull-down assays (solid line) and gel-shift assays (dashed line). [B]
Biotinylated oligonucleotide containing sequences -108 to -39 of the p15Ink4B promoter
was incubated with HepG2 nuclear extracts and pulled-down. DNA-bound proteins in
precipitates were analyzed by immunoblotting. [C] ChIP analysis of interactions of Sp1
with the p15Ink4B promoter. The input fraction corresponded to 1 % of the chromatin
solution of each sample before IP.
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3.2. DLX4 blocks the DNA-binding ability of Sp1, independently of Smad proteins

In subsequent experiments, we sought to determine whether DLX4 blocks the
DNA-binding ability of Sp1, independently of Smad proteins. Gel-shift assays were
performed to test the ability of DLX4 to prevent Sp1 from binding sequences of the
minimal p15Ink4B promoter region (nucleotides -88 to -63). Addition of increasing
amounts of recombinant FLAG-tagged DLX4 blocked the binding of recombinant Sp1
to the DNA probe (Figure 36A). In contrast, addition of increasing amounts of FLAGtag alone did not affect the DNA-binding ability of Sp1 (Figure 36A).

Because DLX4 blocks DNA-binding ability of Sp1, we also investigated whether
DLX4 blocks Sp1-induced transcription, independently of Smads. We performed
reporter assays using a synthetic promoter that comprised tandem Sp1-binding sites
(Figure 36B). Enforced expression of DLX4 in Smad4-deficient MDA-MB-468 cells
inhibited activity of the Sp1-driven promoter (Figure 36B). Conversely, knock-down of
DLX4 in MCF-7 cells stimulated Sp1-driven promoter activity (Figure 36B).
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Figure 36. DLX4 blocks DNA-binding ability of Sp1
[A] Gel shift analysis using a

32

P-labeled oligonucleotide containing nucleotides -88 to

-64 of the p15Ink4B promoter (refer figure 35A). Recombinant Sp1 protein was
incubated with increasing amounts of in vitro translated FLAG-DLX4 and FLAG-tag.
Gel-shifted DNA-bound Sp1 is indicated. [B] MDA-MB-468 cells were co-transfected
with empty vector (-DLX4) or DLX4, together with the Cignal Sp1 reporter construct
driven by a synthetic promoter comprising tandem Sp1-binding sites (left). Sp1-driven
promoter activity was, likewise, assayed in MCF-7 cells that were co-transfected with
non-targeting shRNA or DLX4 (sh90) shRNA (right). Shown are average relative F-Luc
activities in three independent experiments each performed in duplicate. Values were
normalized by activity of co-transfected R-Luc.
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C. CONCLUSION

Cooperative interactions between Smad proteins and Sp1 are important for
TGF-β-induced transcription of CDK inhibitor genes. In this chapter, we identified the
mechanism of how DLX4 blocks Smad/Sp1-mediated transcription. We found that
DLX4 does not prevent the interaction between Sp1 and Smad4, but blocks the
interactions of Sp1 and Smad proteins with the p15Ink4B promoter. We also
demonstrate that DLX4 directly binds to the DNA-binding domain of Sp1, and inhibits
the DNA-binding ability of Sp1. Together, these results indicate that DLX4 inhibits
Smad/Sp1-mediated transcription by inhibiting the DNA-binding ability of Sp1, in
addition to preventing Smad4 from interacting with R-Smads as identified in Chapter 4.
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CHAPTER 6: DISCUSSION

A. DLX4 COUNTERACTS KEY TRANSCRIPTIONAL CONTROL MECHANISMS OF
THE TGF-β
β CYTOSTATIC PROGRAM

The TGF-β cytostatic program is essential for maintaining normal tissue
homeostasis. Gene responses that are central to the TGF-β cytostatic program include
induction of the CDK inhibitors p15Ink4B and p21WAF1/Cip1 and repression of c-myc.
These gene responses are tightly regulated by a repertoire of transcriptional regulators
that include Smad proteins, Sp1 and c-myc (3, 4). My studies in Chapter 3 (Aim 1)
demonstrate that DLX4, a homeodomain protein that is expressed in many types of
cancers, blocks the anti-proliferative effect of TGF-β by preventing G1 arrest. DLX4
inhibits TGF-β-induced expression of p15Ink4B and p21WAF1/Cip1 and blocks TGF-βmediated repression of c-myc expression. In addition, my studies demonstrate that
DLX4 induces c-myc expression independently of TGF-β signaling. My studies in
Chapter 4 (Aim 2) and Chapter 5 (Aim 3) identify and characterize several distinct
mechanisms by which DLX4 inactivates transcriptional control of the TGF-β cytostatic
program.
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1. DLX4 sequesters Smad4 and prevents Smad4 from binding R-Smads

The formation of transcriptional complexes of Smad4 and activated R-Smads
upon TGF-β stimulation is essential for Smad-mediated transcription (10, 12). My
studies indicate that DLX4 does not alter Smad phosphorylation, expression or nuclear
translocation (Figure 22). However, my studies identify that DLX4 blocks Smad
transcriptional activity (Figures 24 and 25) by directly binding to Smad4 and preventing
Smad4 from binding to R-Smads (Figures 27 and 28). Smad interactions might also be
prevented by the binding of DLX4 to R-Smads, as we observed that DLX4 directly
binds to Smad2 (Figure 28). However, binding of DLX4 to Smad2 was much weaker
than to Smad4. Because Smad4 and R-Smads interact with one another via their MH2
domains (201), our finding that DLX4 binds the Smad4 MH1 domain is somewhat
surprising. One explanation could be that binding of DLX4 to the Smad4 MH1 domain
induces a conformational change such that the MH2 domain of Smad4 is unable to
interact with R-Smads (Figure 37). One way to test this would be to perform X-ray
crystallography studies of DLX4 interactions with Smad proteins. However, since
Smad proteins bind DNA via their MH1 domains, the binding of DLX4 to the MH1
domain is consistent with the observed ability of DLX4 to block the ability of Smads to
bind DNA (Figure 31). Smad proteins have been reported to interact with a variety of
other transcription factors (reviewed in (203)). However, most of these other
transcription factors interact with the MH2 domain of Smad proteins, and very few
interact with the MH1 domain.
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Figure 37. Predicted model of DLX4, Smad4 and Sp1 interactions
In the absence of TGF-β stimulation, Sp1 binds to the GC box element on target gene
promoters to drive basal transcription [A]. Upon TGF-β stimulation, R-Smads and
Smad4 form transcriptional complexes with Sp1 and induce gene transcription [B]. In
cells that highly express DLX4, DLX4 forms an inactive complex in the nucleus by
directly binding to both Sp1 and Smad4 and represses gene transcription [C]. TGF-β
stimulation activates R-Smads and induces their translocation into the nucleus.
However, activated R-Smads fail to bind to Smad4 due to the blocking effect of DLX4.
As a consequence, TGF-β cannot induce transcription of target genes [D].
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2. Interaction of DLX4 and Sp1

Binding affinity and selectivity of Smad complexes for target gene promoters are
principally dictated by interactions of Smads with other DNA-binding factors (10, 201).
Similarly, binding affinity and selectivity of several homeodomain proteins are
modulated by interactions with other transcriptional regulators (204, 205). Sp1 is an
important binding partner of Smad proteins that cooperates with Smads to induce
transcription of p15Ink4B and p21WAF1/Cip1. Upon TGF-β stimulation, Sp1 binds to MH1
domain of Smad4 and the MH2 domain of Smad2 to form Sp1/Smad complexes that
bind to the promoters via their respective binding sites (37, 51).

Surprisingly, we

observed that DLX4 does not prevent Sp1 from associating with Smad4 in TGF-βstimulated cells (Figure 32A). Notably, DLX4 seemed to facilitate Smad4-Sp1
interactions even in the absence of TGF-β stimulation (Figure 32A). Furthermore, my
studies demonstrate that DLX4 directly binds the DNA-binding domain of Sp1 and
impairs the DNA-binding ability of Sp1 (Figures 34, 35 and 36). This study is the first to
demonstrate that a homeodomain protein directly interacts with Sp1 and modulates
Sp1 activity. Since my studies demonstrated that DLX4 directly binds to Smad4 and to
Sp1, we speculate that DLX4 inhibits p15Ink4B transcription by two integrated
mechanisms. Firstly, DLX4 might recruit Sp1 and Smad4 to form a transcriptionally
inactive DLX4-Smad-Sp1 complex that is unable to bind TGF-β-activated R-Smads.
Secondly, by directly binding to the DNA-binding domains of Smad4 and of Sp1, DLX4
might dislodge Smad4 and Sp1 from the p15Ink4B promoter (Figure 37). Because
transcription of p21WAF1/Cip1 is also induced by TGF-β via cooperative interactions
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between Sp1 and Smad proteins (38), DLX4 might inhibit p21WAF1/Cip1 transcription by
a similar mechanism.

3. Induction of c-myc by DLX4

My studies indicate that DLX4 induces expression of c-myc by two
mechanisms. On one hand, DLX4 can block the ability of TGF-β to repress c-myc
promoter activity (Figure 20). As previously discussed in Chapter 1, interaction of the
repressive complex comprising Smad3, Smad4 and E2F4/5, DP1 and p107 with the
TIE element in the c-myc promoter blocks c-myc transcription (46, 47) (Figure 5A).
Because DLX4 blocks Smad4 from binding activated Smad3 (Figure 27A), DLX4 might
block formation of the repressive complex and thereby derepress the c-myc promoter.
My studies also demonstrate that DLX4 induces c-myc expression independently of
TGF-β/Smad signaling. One possibility is that DLX4 directly activates the c-myc
promoter. The c-myc promoter contains multiple TAAT core motifs that are recognized
by homeodomain proteins. Indeed, it has been reported that another homeodomain
protein, HOXB4, induces c-myc promoter activity (206).

Our finding that DLX4 induces expression of c-myc independently of TGF-β
signaling has several implications. Firstly, induction of c-myc by DLX4 provides a
competing mitogenic signal against the TGF-β cytostatic program. c-myc induces
expression of numerous cell cycle facilitators such as Id2, cdc25A and cyclin D1 (57,
58, 207, 208). Secondly, DLX4-induced c-myc expression might lead to downregulated expression of p15Ink4B and p21WAF1/Cip1, because transcription of these genes
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is repressed by c-myc (62, 63). The repression of p15Ink4B transcription by c-myc has
some similarity to our observations with DLX4. We found that interaction of Sp1 with
Smad4 was not disrupted by DLX4. Feng et al., likewise, reported that c-myc does not
compete with Sp1 for interaction with Smads (62). These authors speculated that by
interacting with activated Smad2/3, c-myc promotes the formation of an inactive
transcription complex with Smad proteins and Sp1. However, there are notable
differences in the mechanisms by which DLX4 and c-myc repress p15Ink4B promoter
activity. In my studies, DLX4 was found to inhibit interactions between Smad4 and RSmads, and to inhibit R-Smad transcriptional activity. In contrast, c-myc does not
inhibit interactions between Smad4 and R-Smads (62). Furthermore, in my studies,
DLX4 was found to inhibit DNA-binding activity of Sp1. In contrast, c-myc does not
affect binding of Sp1 to the p15Ink4B promoter (62). DLX4 might, therefore, repress
p15Ink4B and possibly also p21WAF1/Cip1 transcription by three distinct, but integrated,
mechanisms: i) by increasing c-myc expression, ii) by preventing Smad4 from binding
R-Smads, and iii) by blocking Sp1 DNA-binding activity.

B. INTERACTIONS BETWEEN DLX GENES AND THE TGF SUPER-FAMILY

1. Cross-regulation of DLX genes and TGF super-family members

The ability of DLX4 to block TGF-β signaling might be related to the functions of
DLX genes in controlling bone morphogenesis and skeletal patterning (1, 129). These
processes are tightly regulated by members of the TGF super-family. Because DLX4
binds Smad4, DLX4 also likely blocks signaling emanating from other receptors of the
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TGF super-family. Indeed, we found that DLX4 inhibited induction of transcriptional
activity by BMP-4 (Figure 26). DLX1 has been reported to inhibit activin signaling
(184). Conversely, signaling by TGF super-family members can modulate expression
or activity of DLX proteins. For example, BMP-2 activates DLX3 transcription (182).
Smad6, an antagonist of BMP signaling, inhibits DLX3 transcriptional activity (183).
Interestingly, we observed that levels of DLX4 protein decreased in cells following
TGF-β stimulation (Figure 18). DLX4 might be a component of a regulatory loop that
blocks TGF-β signaling and is conversely regulated by TGF-β. This feedback
mechanism might play an important role in controlling normal embryogenesis and
homeostasis.

2. Binding specificity of homeodomain proteins to Smads

Transcription factors encoded by homeobox genes are characterized by their
conserved helix-turn-helix DNA-binding homeodomain (209). Our findings that binding
of DLX4 to the MH1 domain of Smad4 is mediated in part through the homeodomain
of DLX4 raises the question of specificity. Transcription factors encoded by various
homeobox genes have been reported to bind Smads, but not all of these interactions
are solely mediated via the homeodomain. For example, proteins encoded by the
Mixer and Milk homeobox genes bind Smad2 through a region distinct from their
homeodomains (181). DLX1 has been reported to bind Smad4, but its binding region
has not been identified (184). Transcription factors encoded by various other
homeobox genes have been reported to bind Smads via their homeodomain.
However, the specificity of homeodomain proteins for different Smads is striking. Most
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of the interactions between homeodomain proteins and Smads reported so far are with
either R-Smads or I-Smads. DLX3 binds Smad6 but not Smad4 (183). HOXA13 binds
Smad1, Smad2 and Smad5 but does not bind Smad4 (185). Furthermore, different
homeodomain proteins bind different domains of Smad proteins. For example, HOXC8
interacts with the MH1 domain of Smad1 (210), whereas HOXA13 binds the MH2
domains of Smad1 (185). Within the homeodomain, the residues of the third helix are
the most highly conserved (127). Less conserved residues of the first and second
helices might govern preferential binding to a specific Smad protein or Smad domain.
My study is the first to demonstrate a direct interaction of a homeodomain protein to
the MH1 domain of Smad4. Indeed, very few transcription factors are known to bind
the MH1 domain of Smad4 (reviewed in (203)). However, it is possible that other
homeodomain proteins could bind Smad4 and potentially block TGF-β-mediated
growth inhibition by a mechanism similar to that of DLX4. Nonetheless, the specificity
of this inhibition could largely depend on the context of the expression of homeobox
genes. Most homeobox genes are expressed in a highly tissue-specific manner (137,
209). In contrast, DLX4 is expressed across diverse malignancies (Table 5). No other
homeobox gene has been reported to be commonly expressed in tumors of lung,
breast, ovary, prostate and hematologic origin. Interference of TGF-β-mediated growth
inhibition by DLX4 could, therefore, be a mechanism common to multiple organ sites.
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C. THE ROLE OF HOMEOBOX GENE DLX4 IN TUMORIGENESIS

1. Resistance of tumors to the anti-proliferative effect of TGF-β
β

Resistance to TGF-β-mediated growth-inhibition is an important feature in the
pathogenesis of most types of tumors (3, 4, 95). This resistance has been attributed to
TGF-β receptor or Smad mutations in several types of tumors, particularly those of
gastrointestinal and pancreatic origin (Table 2). Resistance of tumor cells to the antiproliferative effect of TGF-β can also stem from down-regulation of TGF-β receptor
expression (211), activation of Smad repressors, repression of Smad activators
(Figure 2) and mutation of downstream targets such as p15Ink4B deletion (212). The
ability of DLX4 to block TGF-β-mediated growth inhibition could explain why tumors
that lack aberrations in core components of the TGF-β signaling pathway can become
resistant to the anti-proliferative effect of TGF-β. It would be important in future studies
to determine whether DLX4 is aberrantly activated in tumors that have TGF-β receptor
or Smad mutations, and what is the effect of DLX4 in these tumors. It is interesting to
note that Ski and SnoN proteins also can block the anti-proliferative effect of TGF-β
and that these proteins are both elevated in many types of cancer. The sno gene is
also located in a chromosomal locus that is frequently amplified in many tumors
(reviewed in (29)). However, the mechanisms for the blocking effect of Ski/Sno are
distinct from that of DLX4. Ski/Sno blocks TGF-β/Smad signaling in a “gene nonspecific” manner by recruiting N-CoR/mSin3/HDAC repressor complexes to Smad4/RSmad transcription complexes (27-29). However, in this study, we demonstrated that
DLX4 blocks TGF-β/Smad signaling by both “gene non-specific” and “gene specific”
113

mechanisms. As discussed earlier, DLX4 blocks TGF-β/Smad signaling by a “gene
non-specific” mechanism via binding Smad4 and preventing binding of Smad4 to TGFβ-activated R-Smads. DLX4 also blocks TGF-β-mediated induction of p15Ink4B and
p21WAF1/Cip1 transcription by a “gene specific” mechanism via forming a transcriptionally
inactive complex with Smad4 and Sp1, and by inducing expression of c-myc, a
repressor of p15Ink4B and p21WAF1/Cip1 transcription.

2. Other roles of DLX4 in tumor progression

A striking aspect of the TGF-β signaling pathway in tumors is its biphasic
function. Many tumors are resistant to the anti-proliferative effect of TGF-β but retain
other TGF-β-mediated mechanisms that promote EMT and metastasis (3, 4). It has
been thought that core components of the TGF-β pathway remain functional in these
tumors, whereas downstream aberrations (such as p15Ink4B deletion) disable the
growth-inhibitory arm of the pathway (3, 4). By sequestering Smad4, DLX4 inactivates
the core pathway and might also block the metastasis-promoting function of TGF-β.
Indeed, DLX4 markedly, but not completely, inhibited TGF-β-induced EMT in NMuMG
cells (Figure 21). The ability of DLX4 to inhibit TGF-β-induced EMT could explain the
association of DLX4 with favorable prognosis in lung cancer patients and its
metastasis-suppressive activity reported by Tomida et al. (178). However, DLX4 levels
in ovarian and breast cancers have been reported to correlate with disease
progression (173, 176). There are several possible explanations for this paradox. As
described in Chapter 1, TGF-β not only induces EMT by Smad-dependent
mechanisms, but also via Smad-independent pathways that involve MAP kinase and
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RhoA activation (88). TGF-β-induced, non-Smad pathways that promote cell migration
might not be inhibited by DLX4. One way to test this possibility is to assay the effect of
DLX4 on cell migration using MDA-MB-468 breast cancer cells that have homozygous
deletion of Smad4. DLX4 could also promote tumor progression by other mechanisms
such as sustained induction of c-myc. For example, c-myc not only stimulates cell
growth but also promotes tumor metastasis (213). In addition, our laboratory has found
that DLX4 promotes tumor angiogenesis by inducing expression of vascular
endothelial growth factor and fibroblast growth factor-2 (FGF-2) (173). The mechanism
that gives rise to overexpression of DLX4 in tumors is unclear. The DLX4 gene maps
to the 17q21.3-q22 region, a chromosomal “hot-spot” that is amplified in ~10% of
breast and ovarian cancers (175, 214). However, DLX4 overexpression occurs in
>50% of these tumors (173, 176) indicating that gene amplification is not the sole
mechanism underlying this overexpression.

3. Functional significance of homeobox genes in cell growth deregulation in
cancers

In addition to the ability of DLX4 to block the TGF-β anti-growth signal identified
in this study, other reports implicate a function for DLX4 in enhancing cell survival. The
anti-apoptotic effect of DLX4 has been associated with its ability to induce expression
of GATA-1 and bcl-2 (171, 190). DLX4 has also been reported to repress expression
of the DNA-damage repair protein BRCA1 in breast cancer, suggesting that DLX4
might play a role in DNA-damage repair (189). Aberrant expression of other homeobox
genes can also promote tumor cell survival and growth. HOXA1 is overexpressed in
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breast cancers and promotes tumor cell survival by inducing bcl-2 expression (215).
HSIX1 is also highly expressed in breast cancers and causes abrogation of the G2
checkpoint by inducing expression of cyclin A1 (162, 163). HOXB7 is overexpressed in
melanomas, breast and ovarian cancers and induces expression of FGF-2 (167, 216).
On the other hand, several homeobox genes can inhibit cell growth, and their
expression is lost in tumors. CDX2 inhibits cell growth by inducing expression of
p21WAF1/Cip1, and CDX2 is down-regulated in colon cancers (152, 217). p53 is a direct
transcriptional target of HOXA5 (145). Loss of HOXA5 expression has been reported
in >60% of breast cancers (145). My study is the first report that functionally links a
homeobox gene that is aberrantly expressed in tumors with resistance to the cytostatic
activity of TGF-β. This study significantly supports a growing body of evidence that
aberrant expression of homeobox genes can deregulate tumor cell growth by a wide
variety of different mechanisms.

D. CONCLUSION

Resistance to the anti-proliferative effect of TGF-β is an important feature in the
pathogenesis of most types of cancers. Resistance of many tumors to TGF-β cannot
be solely explained by TGF-β receptor and Smad mutations or deletions. My studies
demonstrate that DLX4 blocks the anti-proliferative effect of TGF-β by disabling key
transcriptional control mechanisms of the TGF-β cytostatic program. My studies also
provide a molecular explanation as to why many tumors are resistant to the growthinhibitory effect of TGF-β in the absence of mutations in core components of the TGFβ signaling pathway (Figure 38). Escape from anti-proliferative signals is an important
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and early step in tumor pathogenesis. DLX4 might therefore, serve as a useful early
detection marker and therapeutic target for multiple types of tumors. At a broader
level, my studies might provide insight into how aberrant activation of a developmental
patterning gene promotes tumor pathogenesis. Conversely, the finding of this study
that DLX4 modulates TGF-β signaling in tumors also provides insights into how
homeobox genes and TGF-β signaling interact to control normal developmental
patterning.
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Figure 38. DLX4 blocks TGF-β
β-induced G1 arrest
TGF-β induces G1 arrest primarily by inducing expression of CDK inhibitors, p15Ink4B
and p21WAF1/Cip1. DLX4 prevents G1 arrest by blocking TGF-β/Smad signaling and by
inducing expression of c-myc, a transcriptional repressor of p15Ink4B and p21WAF1/Cip1,
independently of TGF-β signaling.
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